 
 
Clinical Investigation Plan Title  Stroke AF  
Clinical Investigation Plan Identifier  Stroke AF  
Study Product  Reveal LINQ™ Insertable Cardiac Monitor  
ClinicalTrials.gov Identifier  [STUDY_ID_REMOVED]  
Sponsor  Medtronic  
[ADDRESS_213572] NE  
Mounds View, MN U.S.A.  [ZIP_CODE]  
Document Title  Stroke AF Clinical Investigation Plan  
Document Version (Date)  4.0 ( 18- DEC -201 8) 
 

Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 1 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
   
 
 
Clinical Investigation Plan  
 
Clinical Investigation Plan/Study Title   
Stroke AF  
 
 
Study Product Name   
[CONTACT_181035] ™ Insertable Cardiac Monitor  
 
 
Sponsor/Local Sponsor   
Medtronic , Inc.  
[ADDRESS_213573] NE  
Mounds View, MN U.S.A. [ZIP_CODE] 
[PHONE_3872] 
 
 
Document Version   
4.[ADDRESS_213574]  know  that it is 
confidential and that it may  not be further  disclosed by [CONTACT_476].  
 
 
  

Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 2 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table of Contents  
 
Table of Contents  ................................................................................................ ......................  2 
Listing of Tables  ................................................................................................ ........................  6 
1. Glossary ................................................................................................ ..............................  7 
2. Synopsis  ...........................................................................................................................  10 
3. Introduction  .....................................................................................................................  14 
3.1. Background  ........................................................................................................................  14 
3.2. Purpose  .............................................................................................................................. 16 
4. Objectives and Endpoints  ................................................................................................ . 16 
4.1. Objectives  ..........................................................................................................................  16 
4.1.1.  Primary Objective(s)  .............................................................................................................. 16 
4.1.2.  Secondary Objective(s)  .......................................................................................................... [ADDRESS_213575] Training Requirements  .............................................................................................  22 
6.7.1.  Investigator / Investigation Site Selection  ............................................................................ [ADDRESS_213576] Consent  ..................................................................................................................  27 
8.3. Randomization and Treatment Assignment  ............................................................................ 29 
8.4. Procedures and Data Collection  ............................................................................................  29 
8.4.1.  Baseline ................................................................................................................................. 29 
8.4.2.  Reveal LINQ ICM Insertion  .................................................................................................... 30 
8.4.3.  Scheduled Follow -up Visits/CareLink Transmissions  ............................................................ 31 
[IP_ADDRESS].  Follow-up Visits  ................................................................................................................. 32 
[IP_ADDRESS].  Follow-up Visits / Remote CareLink Transmissions  ........................................................... 33 
8.4.4.  Unscheduled Follow -up Visits  ............................................................................................... 33 
8.4.5.  Stroke/TIA Recurrence  .......................................................................................................... [ADDRESS_213577] Withdrawal or Discontinuation  ..................................................................................  37 
9. Risks and Benefits  ............................................................................................................ 37 
9.1. Potential Risks  .................................................................................................................... 37 
9.2. Potential Benefits  ................................................................................................................  37 
9.3. Risk-Benefit Rationale  ..........................................................................................................  37 
10. Adverse Events and Device Deficiencies  ....................................................................... 38 
10.1.  Adverse Event Assessment  .............................................................................................  38 
10.1.1.  Adverse Events .................................................................................................................. 38 
10.1.2.  Device Deficiencies  ............................................................................................................ 39 
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 4 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  10.1.3.  Processing Updates and Resolution  .................................................................................. 39 
10.2.  Definitions/Classifications  ...............................................................................................  [ADDRESS_213578] Death .................................................................................................................... 45 
[IP_ADDRESS].  Death Data Collection  .................................................................................................... 45 
[IP_ADDRESS].  Death Classification and Reporting  ................................................................................ [ADDRESS_213579] Complaint Reporting  ..........................................................................................  47 
11. Data Review Committees  ..............................................................................................  48 
11.1.  Clinical Events Committee (CEC) Review  ..........................................................................  48 
12. Statistical Design and Methods  .....................................................................................  49 
12.1.  Primary Objective  ..........................................................................................................  49 
i. Hypothesis  .................................................................................................................................... 50 
ii. Endpoint Definition  ................................................................................................................... 50 
iii. Performance Requirements  ...................................................................................................... 50 
iv. Rationale for Performance Criteria  ........................................................................................... 50 
v. Sample Size Determination  ....................................................................................................... 51 
vi. Analysis Methods  ...................................................................................................................... 51 
vii. Determination of Patients/Data for Analysis  ............................................................................ 51 
12.2.  Secondary Objective  ......................................................................................................  52 
i. Hypothesis  .................................................................................................................................... 52 
ii. Endpoint Definition  ................................................................................................................... 52 
iii. Perfo rmance Requirements  ...................................................................................................... 52 
iv. Sample Size Determination  ....................................................................................................... 52 
v. Analysis Methods  ...................................................................................................................... 53 
vi. Determination of Patients/Data for Analysis  ............................................................................ 53 
13. Ethics  .............................................................................................................................  53 
13.1.  Statement(s) of Compliance  ........................................................................................... [ADDRESS_213580] Access to Source Data/Documents  ......................................................................... [ADDRESS_213581]  Retention  ...........................................................................................................  56 
14.7.1.  Investigator Records  .......................................................................................................... 56 
14.7.2.  Investigator Reports  .......................................................................................................... 56 
14.7.3.  Sponsor Records  ................................................................................................................ 57 
14.7.4.  Sponsor Reports  ................................................................................................................ 58 
14.8.  Publication and Use of Information  ..................................................................................  58 
14.8.1.  Publication Committee  ...................................................................................................... 58 
14.8.2.  Management of Primary, Secondary and Ancillary Publications  ...................................... 59 
14.8.3.  Criteria for Determining Authorship  ................................................................................. 59 
14.8.4.  Transparency  ..................................................................................................................... 60 
14.9.  Suspension or Early Termination  .....................................................................................  60 
14.9.1.  Planned Study Closure ....................................................................................................... 60 
14.9.2.  Early Termination or Suspension ....................................................................................... 60 
[IP_ADDRESS].  Study -wide Termination or Suspension  ......................................................................... 61 
[IP_ADDRESS].  Investigator/Site Termination or Suspension  ................................................................ 61 
14.9.3.  Procedures for Termination or Suspension  ....................................................................... 61 
[IP_ADDRESS].  Medtronic -Initiated and Regulatory Authority -Initiated  ............................................... 61 
[IP_ADDRESS].  Investigator -Initiated  ..................................................................................................... 62 
[IP_ADDRESS].  Ethics Committee -Initiated ............................................................................................ 62 
15. References  .....................................................................................................................  63 
16. Version History  ..............................................................................................................  65 
 
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 6 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Listing of Table s 
Table 1: Reveal LINQ System Component Information  21 
Table 2: Data Collection and Study Procedures  26 
Table 3: Reveal LINQ ICM Programming  31 
Table 4: Follow -up Visit / CareLink Transmission Schedule  32 
Table 5: Recommended Programming Parameters for Medtronic IPG, ICD or CRT Devices  34 
Table 6: Adverse Event Definitions  40 
Table 7: Adverse Event Classification Responsibilities  44 
Table 8: AE Reporting Requirements  45 
Table 9: Subject Death Classification 47 
Table 10: Investigator Reports per Medtronic Requirement s 57 
Table 11: Sponsor Reports  58 
 
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 7 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  1. Glossary 
Term  Definition  
Adverse Event (AE)  
(Adapted from ISO [ZIP_CODE]:2011, 3.2)  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, 
users or other persons, whether or not related to the investigational medical device  
NOTE 1: This definition includes events related to the investigational medical device or the comparator. 
NOTE 2: This definition includes events related to the procedures involved.  
Adverse Device Effect (ADE)  
(ISO [ZIP_CODE]:2011, 3.1)  Adverse event related to the use of an investigational medical device  
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, instal lation, 
or operation, or any malfunction of the investigational medical device. 
NOTE 2: This definition includes any event resulting from an error use or 
from intentional misuse of the investigational medical device.  
American Heart Association (AHA)  A no n-profit organization in the [LOCATION_002] that fosters appropriate 
cardiac care in an effort to reduce disability and deaths caused by 
[CONTACT_180994].  
Antiplatelet (AP)  Antiplatelet  agents decrease platelet aggregation (clumpi[INVESTIGATOR_180971]) and 
inhibit thrombus formation. 
Atrial Fibrillation (AF)  Atrial fibrillation  (also called AFib or AF) is a quivering or irregular heartbeat 
(arrhythmia) that can lead to blood clots, stroke, heart failure and other 
heart -related complication.   
Cardiac Death  A death directly related to the electrical or mechanical dysfunction of the 
heart.  
Cardiac Resynchronization Therapy (CRT)  CRT is a clinically proven treatment option for some individuals with heart 
failure. A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized 
pattern. This may improve the heart’s ability  to pump blood and oxygen to 
your body.   
Cardiovascular Related  An adverse event rela ting to the heart and the blood vessels or the 
circulation.  
CHADS  Score  Clinical prediction rules for estimating the risk of stroke in patients with 
non-rheumatic atrial fibrillation. A high score corresponds to a greater risk 
of stroke, while a low score  corresponds to a lower risk of stroke.   
Carotid Endarterectomy (CEA)  A surgical procedure used to reduce the risk of stroke by [CONTACT_180995]. Endarterectomy is 
the removal of material on the i nside of an artery.   
Clinical Event Committee (CEC)  An independent committee of experts not participating in the clinical study 
that provides adjudication of study specific endpoints and/or events 
utilizing study -specific or consensus definitions available in the field.  
Clinical Investigation Plan (CIP)  The present document describing the study protocol.  
Complication   An adverse event that results in death, involves any termination of 
significant device function, or requires invasive intervention.  
Non -invasive: when applied to a diagnostic device or procedure, means one 
that does not by [CONTACT_180996]:  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 8 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Term  Definition  
• Penetrate or pi[INVESTIGATOR_180972], the ocular cavity or the urethra or  
• Enter the ear beyond th e external auditory canal, the 
nose beyond the nares, the mouth beyond the 
pharynx, the anal canal beyond the rectum, or the vagina beyond the cervical os  
For purposes of this part, blood sampling that involves simple venipuncture 
is considered non- invasiv e, and the use of surplus samples of body fluid or 
tissue that are left over from samples taken for non- investigational 
purposes is also considered non -invasive.  
Coronary Artery By[CONTACT_60488] (CABG)  Coronary artery by[CONTACT_4897], also known as cor onary artery by[CONTACT_15803], and colloquially heart by[CONTACT_180997], is a surgical 
procedure to restore normal blood flow to an obstructed coronary artery.   
Cryptogenic Stroke  A stroke without an obvious explanation  (of unknown origin).  
Device Deficiency (DD)  
(ISO [ZIP_CODE]:2011, 3.15)  
 Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance.  
NOTE: Device deficiencies include malfunctions, use errors and inadequate 
labeli ng  
Electronic Case Report Forms (eCRF)  Forms where the clinical data are collected. eCRF is the electronic version of 
case report forms.  
Ethical Committee / Institutional Review Board 
(EC / IRB)  Any board, committee, or other group formally designated by [CONTACT_180998], to approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects. The primary purpose of such review is to assure the protection of the rights and welfare of the human 
subjects.  
Hospi[INVESTIGATOR_059]  A therapeutic inpatient hospi[INVESTIGATOR_059] (excludes outpatient and emergency 
room visits) lasting greater than or equal to 24 hours. 
Insertable Cardiac Defibrillator (ICD)  A device implantable inside the body, able to perform cardioversion, 
defibrillation, and pacing of the heart. 
Insertable Cardiac Monitor (ICM)  An implantable loop recorder, also known as an insertable cardiac monitor, 
is a small device that is implanted just under the skin of the chest for long 
term cardiac monitoring.  
Ischemic Stroke (IS)  Ischemic stroke  occurs as a result of an obstruction within a blood vessel 
supplying blood to the brain. 
Non -cardiac Death  A death not classified as a cardiac death  
Non -sudden Cardiac Death  All cardiac deaths that are no t classified as sudden deaths, including all 
cardiac deaths of hospi[INVESTIGATOR_54382]. 
Observation  Any adverse event that is not a complication.  
Note 1: Only system or procedure related AEs will be classified as 
Complication or Observation.  
Oral anticoagulation (OAC)  Anticoagulant  agent s prevent or reduce coagulation of blood.  
Remote Data Capture (RDC)  An interface that allows site users at sites to enter data directly into the 
study database via a web interface. RDC is an example of Electronic Data 
Capture method or EDC.  
Reveal LINQ ICM Procedure Related  
 An adverse event that occurs that is directly related to the implantation or 
modification of the Reveal LINQ system.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 9 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Term  Definition  
Reveal LINQ ICM System Related  
 An adverse event that results from the presence or performance (intended 
or otherwise) of any component of the system (including: Reveal LINQ ICM, 
Programmer, Patient Assistant, and MyCareLink Patient Monitor).  
Serious Adverse Event (SAE)  
(Adapted from ISO [ZIP_CODE]:2011, 3.37)  
 Adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject, that either 
resulted in 
1. a life-threatening illness or injury, or  
2. a permanent impairment of a body structure or a 
body function, or  
3. in-patient or prolonged hospi[INVESTIGATOR_059], or 
4. medical or surgical intervention to prevent life -
threatening illness or injury or permanent impairment to a body structure or a body function,  
c) led to fetal distress, fetal death or a congenital abnormality or birth 
defect  
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure 
required by [CONTACT_10396], without serious deterioration in health, is not 
considered a serious adverse event.   
Stroke  
 Hemorrhagic or Ischemic stroke with rapid onset of a focal or global 
neurological deficit or other neurological signs/symptoms consistent with 
stroke.  
Stroke Diagnosis  Diagnosis will be determined by [CONTACT_779]’s neurologist clinical evaluation 
and include clinical signs and symptoms consiste nt with focal or global 
neurological deficit in addition to one or more of the following:  
• Neuroimaging procedure (CT, MR, or cerebral angiogram)  
• Lumbar Puncture (i.e. subarachnoid hemorrhage)  
Sudden Cardiac Death (SCD)  Natural death due to cardiac causes,  indicated by [CONTACT_54444]; preexisting heart disease may have been known to be present, but the time and mode of death are unexpected. If time of onset cannot be determined, SCD will alternatively be defined as any unexpected cardiac death occurring out of 
the hospi[INVESTIGATOR_54381].  
Transient Ischemic Attack (TIA)  New focal neurological deficit with rapid symptom resolution (usually 1 – 2 
hours), always within 24 hours without tissue injury (based on 
neuroimaging).  
Unavoidable Adverse Event  An Adverse Event inherent to a surgical procedure that is expected to occur 
in all subjects for a projected duration according to the Investigator’s 
opi[INVESTIGATOR_1649], includin g, but not limited to:  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 10 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Term  Definition  
Event Description  Timeframe 
(hours) from the 
Surgical 
Procedure 
Anesthesia related nausea / vomiting  24 
Low-grade fever (<100°F or 37.8°C)  48 
Pocket site / Incisional pain  72 
Mild to moderate bruising / ecchymosis  168 
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
Shoulder pain/discomfort/stiffness related to 
shoulder immobilization during procedure  [ADDRESS_213582] Name  [CONTACT_181036]™  System  
Sponsor  Medtronic, Inc.  
[ADDRESS_213583] NE  
Mounds View, MN  [ZIP_CODE] 
U.S.A.  
Indication under 
investigation  The Reveal LINQ system is being used in accordance with the indications for 
the device.  
Investigation Purpose  The purpose of the Stroke AF study is to compare the incidence of atrial 
fibrillation (AF) through 12 months between continuous cardiac rhythm 
monitoring with the Reveal LINQ™ Insert able Cardiac Monitor (ICM) 
(continuous monitoring arm) and standard of care (SoC) medical treatment (control arm) in subjects with a recent ischemic stroke of presumed known 
origin.   
Product Status  The Stroke AF study will be conducted using the components of the 
Medtronic Reveal LINQ system, as described in the below.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213584] -market study. The Stroke AF study will compare the incidence rate of AF 
through 12 months between the continuous monitoring arm and the control 
arm in subjects with a recent ischemic stroke of presumed known origin.  
Randomization  Once enrolled, subjects will be randomized 1:1 (continuous monit oring vs 
control).  
Treatment  Subjects randomized to the continuous monitoring arm will have a Reveal 
LINQ ICM inserted within [ADDRESS_213585] of care.  
Sample Size  The study will be conducted at approximately 40 study sites in the United 
States (U.S.). Approximately [ADDRESS_213586].  
Inclusion Criteria  • Subject has had an ischemic stroke believed to be due to sma ll vessel 
disease, large vessel cervical or intracranial atherosclerosis within the past 10 days  
• Subject is willing and able to undergo study requirements and expected to be geographically stable during study follow -up 
• Subject is [ADDRESS_213587] one of the following additional 
risk factors for stroke:  
o Congestive heart failure  
o Hypertension (Systolic Blood Pressure >140)  
o Diabetes Mellitus  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 12 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  o Prior Stroke (>90 days ago, other than study  qualifying index event)  
o Vascular disease (e.g. coronary artery disease, heart attack, 
peripheral artery disease and complex aortic plaque)  
Exclusion Criteria  • Subject has had a cryptogenic stroke  
• Subject has had a cardioembolic stroke  
• Subject has untreated hyperthyroidism  
• Subject has had a recent myocardial infarction <1 month of stroke 
• Subject has had a recent cardiac surgery (e.g. coronary artery by[CONTACT_13786] (CABG)) <1 month of stroke  
• Subject has a mechanical heart valve  
• Subject has valvular d isease requiring immediate surgical intervention  
• Subject has documented prior history of atrial fibrillation or atrial flutter  
• Subject has permanent indication for oral anticoagulation  
• Subject has permanent contraindication to oral anticoagulation such that 
detection of AF would not change medical management, based on enrolling investigators judgment  
• Subject is enrolled in a concurrent study that may confound the results of this study. Co -enrollment in any concurrent clinical study ( including 
registries) requires approval of the study manager or designee.  
• Subject’s life expectancy is less than 1 year  
• Subject is pregnant  
• Subject has or is indicated for implant with a pacemaker, ICD, CRT, or an 
implantable hemodynamic monitor  
• Subject wi th a medical condition that precludes the patient from 
participation in the opi[INVESTIGATOR_180973]/component -related, Reveal LINQ ICM procedure 
related, cardiovascular related AEs, and all serious adverse  events leading to 
death will be collected throughout the study duration, starting at the time of 
signing the consent form.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 13 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Clinical Procedures  
Study Procedure Baseline  LINQ  
Insertion* 1, 6 and 12 
Month  
Follow -up 3, 9 Months  
Remote 
Follow -up* Recurring 6 
Month  
Follow -up 
(through 
study exit)  Unscheduled 
Follow -up Stroke/TIA 
Recurrence  
Informed Consent  X       
Inclusion/Exclusion Assessment  X       
Randomization  X       
Demographics, Medical History  X       
Cardiovascular Medications  X  X  X   
TOAST1  X      X 
NIH Stroke Scale X      X 
Modified Rankin Scale  X  X    X 
EQ-5D X  X     
Blood Draw  X 
(if available)        
System & Procedure Information*  X*      
Full Reveal LINQ Interrogation or 
CareLink Transmission*  X* X* X* X* X* 
(if available)  X* 
(if available)  
AF Assessment    X  X X X 
Symptom Assessment    X  X X  
Stroke/TIA Assessment    X  X X  
Adverse Events   
 
  
As they occur  
 Device Deficiencies  
System Modifications*  
Crossover  
Study Deviations  
Subject Exits  
Death  
1Trial of Org [ZIP_CODE] in Acute Stroke Treatment  
* Subjects with a Reveal LINQ ICM  
 
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 14 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  3. Introduction  
3.1. Background  
Stroke is a devastating disease. In the [LOCATION_002] (U.S.) more than 780,000 people experience a new 
or recurrent stroke each year; approximately 600,[ADDRESS_213588] attacks and 180,000 are 
recurrent attacks. About 20% of patients die within the f irst year after having a stroke and another 20% 
are bound to a nursing home for the rest of their life. Furthermore, stroke is the fifth leading cause of death in the U.S. (when considered separately from other cardiovascular diseases) and the leading caus e 
of serious long -term disability in the U.S. (Dariush Mozaffarian, 2015) . 
Of all strokes, 87% are ischemic (Dariush Mozaffarian, 2015) , which occur as a result of decreased or 
insufficient blood flow to the brain. Patients with ischemic stroke (IS) are often treated with antithrombotic therapy. For most patients with IS, the mainstay of treatment is anti -platelet (AP) 
therapy with aspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745], or aspi[INVESTIGATOR_248]+ extended release dipyridamole. However, patients with IS 
who have been diagnosed with atrial fibrillation (AF) are normally treated with long -term oral 
anticoagulation (OAC), per recommendations within the AHA/ASA 2014 guidelines. OAC is dramatically 
more effective at pr eventing recurrent IS than AP therapy in patients with AF  (Owen, 2009) . In contrast, 
for patients without AF (or other rare cardiac sources of embolism), OAC has not been shown more 
effective than AP therapy. Therefore, detection of AF after IS is crucial, as it results in an important 
change in the administration of antithrombotic therapy from AP to OAC, thereby [CONTACT_180999].  
Epi[INVESTIGATOR_180974], which makes detection of AF based on pat ient’s symptoms 
unreliable (L. M. Christensen, 2014)  (S. Adam Strickberger, 2005) .  Additionally, due to its epi[INVESTIGATOR_180975], AF is difficult to detect via intermittent monitoring techniques (Paul D . Ziegler, 2009). While 
AHA/ASA guidelines recommend cardiac monitoring of patients for up to 30 days after stroke, the 
optimum duration of monitoring is not known. It has generally been shown that longer durations of cardiac monitoring result in higher rates of AF detection after stroke. The advent of insertable cardiac 
monitors (ICM) allows continuous monitoring to detect infrequent epi[INVESTIGATOR_180976] [ADDRESS_213589] infrequent but clinically important p aroxysms of 
AF (William C. Choe, 2015) . 
Studies to date suggest that AF is present in ~4 -25% of patients with a recent IS of presumed known 
origin, but this has only been examined using short term (up to 3 weeks) or intermittent monitoring. Rabinstein et al (2013) compared the rate of detection of AF over a three -week period of cardiac 
monitoring in 66 patients with cryptogenic stroke to an equal number of patients with stroke of known origin. Overall, there was no difference in detection rate between cryptogenic stroke and stroke of 
known origin (25% vs 14%, respectively, P=0.12). However, in patients over 65 years, the rates of 
detection were 27% and 25% respectively, whereas in younger patients, more AF was found in those 
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 15 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  with  cryptogenic stroke (21% vs 0%, p=0.03). Similarly, Sposato et al (2012) found that continuous 
cardiac monitoring during hospi[INVESTIGATOR_180977] a substantial number of patients 
with non -cryptogenic stroke. Other studies have shown that  the presence of atherosclerotic risk factors 
as denoted by [CONTACT_181000]2 score predicts the risk of newly detected AF after IS, regardless of stroke 
mechanism.  Lastly, Grond et al (2013) found that of a total of [ADDRESS_213590] stroke or TIA, 
unknown AF was detected in 49 patients (4.3% by 72 -hour  ECG). In summary, these data suggest that AF 
is present in patients with a recent IS of presumed known origin, but this has only been examined using 
short term (up to 3 weeks) or intermittent monitoring. To date, there is yet to be a published study that 
has used an ICM for AF detection specifically in patients with stroke of presumed known origin.  
The occurrence of a first stroke dramatically increases the risk of a second stroke.  About 25% of all IS 
occur in patients who have had a prior IS (recurrent IS)  (Ralph L. Sacco, et al., 2006) . Recurrent ischemic 
strokes are generally more severe than first strokes, and recurrent strokes are more costly, disabling, 
and fatal. Addit ionally, recurrent stroke is the most likely major adverse event after a first IS. Therefore, 
in patients with a first stroke, prevention of recurrence (secondary prevention) is the primary goal of therapy.  
Secondary prevention of IS rests on determining and addressing the risk factors for future stroke. For 
example, patients with stroke ipsilateral to carotid stenosis are treated with carotid endarterectomy (CEA), which has been proven to reduce the risk of recurrence. Although strokes are classified by 
[CONTACT_181001], definitive identification of the cause of stroke is often difficult, and many patients have 
multiple potential causes or have no clear cause. It is therefore not always possible to tailor stroke 
prevention to the cause of the prior stroke. Rather , preventive therapi[INVESTIGATOR_180978]. Importantly, the effectiveness of a preventive therapy does not prove that the target of that therapy caused the index stroke. Rather, it proves that the intervention 
addr essed a risk factor for future stroke.  
Both persistent AF and paroxysmal AF are potent predictors of first and recurrent stroke. More than 
75,000 cases of stroke per year are attributed to AF  (Ralph L. Sacco, et al., 2006) . AF is a major risk factor 
in this patient population, and it often goes undetected due to its epi[INVESTIGATOR_180979]. 
While guidelines do recommend cardiac monitoring of patients after stroke, the optimum duration of 
monitoring in all patients with stroke is not known. For most patients standard of care appears to involve monitoring these patients for [ADDRESS_213591] better rates of detection of AF after stroke. The advent of 
insertable cardiac monitors (ICM) allows detection of infrequent epi[INVESTIGATOR_180976] [ADDRESS_213592] suffered a cryptogenic stroke, or an embolic stroke of an u nknown source 
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 16 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  (ESUS). The CRYSTAL AF study demonstrated that continuous monitoring via ICM is superior to standard 
of care for detecting AF after cryptogenic stroke. At 6 months, AF had been detected at a rate of 8.9% in 
the ICM group vs 1.4% of patients in the control group. By 12 months, AF had been detected at a rate of 
12.4% in the ICM group vs 2.0% in the control group  (Tommaso Sanna, 2014) . While the CRYSTAL AF 
data is promising for patients with a cryptogenic stroke, it remains unclear what the long- term rate of AF 
is in the IS patient population with a presumed known origin. Many post IS patients have risk factors for AF, regardless of the cause of their stroke. Newly detected epi[INVESTIGATOR_180980] 28% of patients with previous thromboembolic events in the TRENDS study  (Paul D. Ziegler, et al., 2010)  and most of 
these epi[INVESTIGATOR_180981].  
3.2. Purpose  
Medtronic is sponsoring the Stroke AF  study. This is a prospective, multi -site, randomized, controlled, 
non-blinded, post -market study.  
The purpose of the Stroke AF study is to compare the incidence rate of AF through [ADDRESS_213593] of care  in subjects with a recent IS of presumed 
known origin (the cause of the stroke is not unknown), specifically due to small vessel disease, large vessel cervical or intracranial atherosclerosis. Upon enrollment subjects will be randomized 1:[ADDRESS_213594] a Reveal LINQ™ ICM inserted within [ADDRESS_213595] of care in subjects with a recent ischemic stroke of presumed known origin. 
Subjects will be randomized 1:1 to the continuous monitoring arm or control arm.  
4.1.1.  Primary Objective(s)  
To compare the incidence rate of AF through 12 months between the continuous monitoring arm vs control arm in subjects with a recent ischemic stroke of presumed known origin.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 17 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  4.1.2.  Secondary Objective(s)  
To compare the incidence rates of AF through the duration of study follow -up between study arms.  
5. Study Design  
5.1. Study Design  
Stroke AF is a prospective, multi-site, randomized, controlled, non -blinded, post -market study. The 
Stroke AF study will compare the incidence rate of AF through 12 months between the continuous 
monitoring arm and the control arm in subjects with a recent ischemic stroke of presumed known origin . 
Once enrolled, subjects will be randomized 1:1 (continuous monitoring vs control). Subjects randomized 
to the continuous monitoring arm will have a Reveal LINQ ICM inserted within [ADDRESS_213596] of care.  
The study is expected to be co nducted at approximately 40 sites located in the [LOCATION_002] (U.S.).  
It is estimated that approximately 496 subjects will be enrolled in the study. Assuming 2% attrition from enrollment to randomization, approximately [ADDRESS_213597] dataset is available for subgroup analysis, a maximum of 50% 
(approximately 248) subjects with lacunar stroke (i.e., small vessel  disease) may be enrolled. Medtronic 
will notify study sites when enrollment of lacunar stroke subjects is no longer allowed, if applicable.  
5.1.1.  Minimization of Bias 
Selection of subjects, treatment of subjects, and evaluation of study data are potential sourc es of bias. 
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Subjects will be screened to confirm eligibility for enrollment with defined inclusion/exclusion 
criteria prior to enrollment.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 18 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • Subjects will be randomized 1:1 to the continuous monitoring arm vs control arm  
• Demographics and medical history will be collected at baseline in order to later assess possible 
characteristics that may influence endpoints.  
• To ensure a widespread distribution of data from study sites, no more than 10% of total expected enrollments (50 subjects) may come  from a single site.  
• It is recommended that all patients at an investigational site with a recent ischemic stroke of 
presumed known origin be screened for the study.  
• All study site and Medtronic personnel will be trained using standardized training materials.  
• Regular monitoring visits will be conducted to verify adherence to the Clinical Investigation Plan and source data.  
• An independent clinical events committee (CEC) will be utilized to regularly review and 
adjudicate reported adverse events and recurrent stroke/TIAs.  
• An independent committee will adjudicate AF epi[INVESTIGATOR_1841]. The committee will be comprised of 
individuals experienced with identifying AF will review the device EGM records to ensure AF was appropriately identified.  
 
In summary, potential sources of bias that may be encountered in this clinical study have been 
considered and minimized by [CONTACT_54415].  
 
5.2. Duration 
The enrollment period is expected to start in early [ADDRESS_213598] enrollment to official study closure (final report) is 
approximately 6.[ADDRESS_213599] participation will  vary based on timing of site 
activation and their enrollment; however, at a minimum, participation of an individual subject will be for [ADDRESS_213600] the treatment and long-term prognosis for patients classified as having an IS of presumed known origin by [CONTACT_181002]. While current guidelines do 
recommend short term (up to 30 days) cardiac monitoring in patients after stroke, evidence generated 
in the Stroke AF study could influence the guidelines with regards to long term (greater than 30 day) 
ICM use post IS.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213601] Descripti on 
6.1. General  
The Stroke AF study will be conducted using the components of the Medtronic Reveal LINQ system.  
 
6.2. Reveal LINQ System  
The Reveal LINQ system consists of 4 main components .  
The Medtronic Reveal LINQ ICM is a programmable device that continuously monitors a patient’s ECG and 
other physiological parameters. The device records cardiac information in response to automatically 
detected arrhythmias and patient activation.  
The devi ce is designed to record the occurrence of an arrhythmia in a patient automatically. Arrhythmias 
may be classified as tachyarrhythmia, brady arrhythmia, pause, atrial tachyarrhythmia, or atrial 
fibrillation. In addition, while experiencing or immediately a fter a symptomatic event, the patient can 
activate the device to record their cardiac rhythm.  
Reveal LINQ ICM:  is a small, leadless device that is inserted under the skin, in the chest. The device uses 
2 electrodes on the body of the device to monitor the patient ’s subcutaneous ECG continuously. The 
device memory can store up to 27 min of ECG recordings from automatically detected arrhythmias and 
up to 30 min of ECG recordings from patient -activated epi[INVESTIGATOR_1841]. The system provides 3 options for 
segmenting the patient -activated epi[INVESTIGATOR_180982]: up to four 7.5 min recordings, up to three 10 min 
recordings, or up to two  15 min recordings. Arrhythmia detection parameters are set to pending 
automatically, based on patient information entered on the programmer during pre-insertion device 
setup: the patient ’s Date of Birth and the clinician ’s Reason for Monitoring the patien t. Arrhythmia 
detection parameters can also be programmed manually by [CONTACT_15370].  

Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 20 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Medtronic Programmer:  is used to set up the device to detect arrhythmias. It also allows the user to view, 
save, or print the information stored by [CONTACT_8121].  
Patient As sistant:  is a hand -held, battery -operated telemetry device that enables the patient to activate 
the recording of cardiac information in the Reveal LINQ ICM while experiencing or immediately after a 
symptomatic event. The clinician uses the recorded information to determine if the symptoms were associated with a cardiac event.  
MyCareLink Patient Monitor:  is used by [CONTACT_181003]. The inserted device communicates wirelessly with this monitor which then transmits the information over a cellular telephone connection to the 
Medtronic CareLink Network. This daily wireless audit transmission is scheduled by [CONTACT_181004] a time when the patient is asleep. At other times, if requested to do so by [CONTACT_181005], the patient can use their monitor to perform a manual device interrogation to gather information from their inserted device and communicate it to their physician. Patien t interaction with their monitor includes 
the initial setup procedure, performing physician -requested data gathering, and responding to physician -
specified notifications on the monitor screen. Refer to the literature that is included with the MyCareLink Patient Monitor for connection and usage information.  
Additional information related to the Reveal LINQ ICM, including indications, contraindications, warnings and precautions can be found in the respective clinician manual.  
   
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 21 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 1: Reveal LINQ System Component Information  
Model Number  Component (Manufacturer)  Investigational or Market -
released in the [LOCATION_002]  
LNQ11 or other 
commercial model  Reveal LINQ Insertable Cardiac Monitor  Market - released  
2090 or other 
commercial model  Medtronic Programmer  Market - released  
960000 or other 
commercial model  Patient Assistant  Market - released  
[ZIP_CODE] or other 
commercial model  MyCareLink Patient Monitor  Market - released  
 
6.3. Intended Population  
The Reveal LINQ system is being used in accordance with the indications for the device. The Reveal ICM is 
indicated for:  
• Individuals with clinical syndromes or situations at increased risk of cardiac arrhythmias.  
• Individuals who experience transient symptoms such as dizziness, palpi[INVESTIGATOR_332], syncope, and chest 
pain that may suggest a cardiac arrhythmia.  
6.4. Packaging 
Labeling and package for all products used in this study will follow the local regulatory requirements.  
Labeling and reference/technical manuals for the Reveal LINQ ICM will be provided under separate cover. 
Labeling for all other market approved system components can be found with each package insert.  
6.5. Equipment  
The following equipment must be available at each site to support study activities:  
• Computer with high speed internet and Windows Internet Explorer for data entry  (Version 6, 8 
or future compatible version) or other compatible browser  
• Medtronic Market Released Programmer  
 
The maintenance and calibration of the equipment used for this study will be assessed by [CONTACT_3452].  
Programmer calibration will not be monitored by [CONTACT_181006], but will be maintained 
by [CONTACT_181007].  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213602] Training Requirements  
6.7.1.  Investigator / Investigation Site Selection 
All clinical investigators managing the subject’s condition during the study must be qualified 
practitioners experienced in the diagnosis and medical treatment of subjects with ischemic stroke.  All physicians performing the insertion procedure must be experienced and/or trained in the handling of 
insertable cardiac monitoring devices.  
The role of the principal investigator [INVESTIGATOR_54365] -to-day conduct of the clinical 
investigation as well as ensure data integrity and the rights, safet y and well -being of the subjects 
involved in the clinical investigation.  
The principal investigator [INVESTIGATOR_67417]: 
• Be qualified by [CONTACT_8640], training, and experience to assume responsibility for the proper 
conduct of the clinical investigation  
• Be experienced in t he diagnoses and treatment of stroke patients  
• Disclosure of potential conflicts of interest that interfere with the conduct of the clinical investigation or interpretation of results  
The principal investigator [INVESTIGATOR_180983]: 
• Has the required number of eligible subjects needed within the recruitment period 
• Has one or more qualified investigators, a qualified investigational site team and adequate facilities for the foreseen duration of the clinical investigation 
Site personnel training will be completed prior to participation in this clinical study.  
6.7.2.  Site Activation  
During the activation process (prior to subject enrollment), Medtronic will train site personnel on the 
clinical investigation plan, relevant standards and regulations, if needed, informed consent, and on data collection and reporting tools. If new members join the study site team, they will receive training on the 
applicable clinical study requirements relevant to their role before contributing  to the clinical study.  
Prior to performing study related activities, all local regulatory requirements shall be fulfilled, including, 
but not limited to the following:  
• Ethics Committee approval of the current version of the CIP and Patient Informed Consent.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 23 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • Fully executed Clinical Trial Agreement (CTA)  
• Curriculum Vitae (CV) of investigators and key members of the investigation site team (as 
required by [CONTACT_1769])  
• Docu mentation of delegated tasks  
• Documentation of study training  
Additional requirements imposed by [CONTACT_181008], if 
appropriate.  
In addition, all participating site staff must be trained on the current version of the CIP and must be 
delegated by [CONTACT_458] [INVESTIGATOR_180984].   
Medtronic will provide each study site with documentation of study site/investigator readiness; this 
letter must be received prior to subject enrollmen t. 
6.8. Product Storage  
The Reveal LINQ ICM is commercially available and will be managed in a manner consistent with other 
market -released product.  
6.9. Product Return  
All explanted devices (devices or leads or activators, etc.) should be returned to Medtronic for analysis 
when permissible by [CONTACT_10976]. To receive a Returned Product Mailer Kit, please contact 
[CONTACT_181009].  
7. Select ion of Subjects  
7.1. Study Population 
Subjects will be screened to ensure they meet all of the inclusion and none of the exclusion criteria prior to study enrollment.  
7.2. Subject Enrollment  
Ethics Committee approval of the Stroke AF Study Clinical Investigation Plan and Informed Consent Form 
must be obtained prior to enrolling patients in the study. Subjects are considered enrolled in the study 
upon signing the informed consent. Informed consent must be obtained prior to performing any study 
related procedures. The subject must be enrolled within [ADDRESS_213603] one of the following additional risk factors 
for stroke:  
• Congestive heart failure  
• Hypertension (Systolic Blood Pressure > 
140)  
• Diabetes Mellitus  
• Prior Stroke  (>90 days ago, other than study qualifying index event)
 
• Vascular disease (e.g. coronary artery disease, heart attack, peripheral artery 
disease and comple x aortic plaque)  Ensure the enrollment of patients who are at 
highest risk.  
 
7.4. Exclusion Criteria  
Exclusion Criteria  Rationale  
Subject has had a cryptogenic stroke  This study aims to fill gaps in knowledge around 
the rate of AF in patients with ischemic stroke of presumed known origin. Data on the incidence 
rate of AF in these patients already exists.  
Subject has had a cardioembolic stroke  Patients with known cardioembolic stroke are 
already being treated with OAC.  
Subject has untreated hyperthyroidism  Avoid possible confounding factors relative to 
patient’s medical condition.  
Subject has had a recent myocardial infarction <1 
month of stroke  Avoid possible confounding factors relative to 
patient’s medical condition.  
Subject has had a recent cardiac surgery  (e.g. 
coronary artery by[CONTACT_4897] (CABG)) <1 month 
of stroke  Avoid possible confounding factors relative to 
patient’s medical condition.  
Subject has a mechanical heart valve  Avoid possible confounding factors r elative to 
patient’s medical condition.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213604] has valvular disease requiring immediate 
surgical intervention  Avoid possible confounding factors relative to 
patient’s medical condition.  
Subject has documented prior history of atrial 
fibrillation or atri al flutter  AF has already been diagnosed in these patients.  
Subject has permanent indication for oral 
anticoagulation  Generally patients begin an OAC regimen once 
diagnosed with AF, these patients are already on 
OAC.  
Subject has permanent contraindication to oral 
anticoagulation such that detection of AF would 
not change medical management, based on enrolling investigators judgment  The detection of AF would not result in a change 
to the patients’ medical management.  
Subject is enrolled in a concurrent study that may 
confound the results of this study.  Co -enrollment 
in any concurrent clinical study (including registries) requires approval of the study manager 
or designee.  Standard exclusion criteria.  
Subject’s life expectancy i s less than [ADDRESS_213605] has or is indicated for implant with a 
pacemaker, ICD, CRT, or an implantable 
hemodynamic monitor  Avoid possible confounding factors relative to 
patients’ cardiac condition.  
Subject with a medical condition that precludes 
the patient from participation in the opi[INVESTIGATOR_180985] 
 
8. Study Procedures  
Prior to performing study related procedures, all sites must have Ethics Board/IRB/MEC as well as 
documentation from Medtronic of site readiness.  
8.1. Schedule of Events  
Clinical data will be collected at baseline,  1, 6, and [ADDRESS_213606] data collected at Reveal LINQ ICM insertion, and 3, and 9 months (Remote CareLink Transmission).  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 26 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Data collection requirements are summarized in the table below. 
Table 2: Data Collection and Study Procedures  
Study Procedure Baseline  LINQ  
Insertion* 1, 6 and 12 
Month  
Follow -up 3, 9 Months  
Remote 
Follow -up* Recurring 6 
Month  
Follow -up 
(through 
study exit)  Unscheduled 
Follow -up Stroke/TIA 
Recurrence  
Informed Consent  X       
Inclusion/Exclusion Assessment  X       
Randomization  X       
Demographics, Medical History  X       
Cardiovascular Medications  X  X  X   
TOAST1  X      X 
NIH Stroke Scale X      X 
Modified Rankin Scale  X  X    X 
EQ-5D X  X     
Blood Draw  X 
(if available)        
System & Procedure Information*  X*      
Full Reveal LINQ Interrogation  or 
CareLink Transmission*  X* X* X* X* X* 
(if available)  X* 
(if available)  
AF Assessment    X  X X X 
Symptom Assessment    X  X X  
Stroke/TIA Assessment    X  X X  
Adverse Events   
 
  
As they occur  
 Device Deficiencies  
System Modifications*  
Crossover  
Study Deviations  
Subject Exits  
Death  
1Trial of Org [ZIP_CODE] in Acute Stroke Treatment  
* Subjects with a Reveal LINQ ICM only  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213607] Consent  
Patient informed consent (PIC) is defined as a legally effective documented confirmation of a subject’s 
(or their legally authorized representative) voluntary agreement to participate in a particular clinical 
study after information has been given to the s ubject on all aspects of the clinical study that are relevant 
to the subject’s decision to participate. This process includes obtaining a Patient Informed Consent Form and an Authorization to Use and Disclose Personal Health Information/Research Authorizat ion/and 
other privacy language as required by [CONTACT_181010]’s Ethics Committee 
and signed and dated by [CONTACT_423] (or their legally authorized representative). A subject may only 
consent after information has been given to t he subject on all aspects of the clinical investigation that 
are relevant to the subject’s decision to participate. Informed consent may be given by [CONTACT_181011] a subject is unable to make the decision to participate in a clinical 
investigation. In such cases, the subject shall also be informed about the clinical investigation within his/her ability to understand.  
Investigators shall consider all subjects who meet eligibility requirements for study participation to avoid 
any bias in the subject population. Prior to enrolling subjects, each site’s Ethics Committee will be 
required to approve the CIP, PIC Form, and any other written study information to be provided to the subjects.  The document(s) must be controlled (i.e. versioned and/or dated) to ensure it is clear which 
version(s) were approved by [CONTACT_20601].  Any adaptation of the sample Consent Form must be reviewed and approved by [CONTACT_181012] s ubjects.  
The investigator must notify the subject (or their legally -authorized representative) of any significant 
new findings about the study that become available during the course of the study which are pertinent 
to the safety and well -being of the subject, as this could impact a subject’s willingness to participate in 
the study. If relevant, approval may be requested from subjects to confirm their continued participation.  
Refer to Appendix C for the sample Patient Informed Consent Form(s). 
Prior to ini tiation of any study -specific procedures, patient informed consent must be obtained from the 
subject (or their legally authorized representative). Likewise, privacy or health information protection 
regulation may require subjects to sign additional forms to authorize sites to submit subject information 
to the study sponsor. The informed consent process must be conducted by [CONTACT_458] [INVESTIGATOR_169225], and the Patient Consent Form and Authorization to Use and Disclose Personal 
Health Information/Research Authorization/other privacy language as required by [CONTACT_181013] (or their legally authorized representative) in a language he/she is able to read and 
understand. The process of patient informed consent must be con ducted without using coercion or 
undue improper influence on or inducement of the subject to participate by [CONTACT_181014]. The informed consent process shall not waive or appear to waive subject’s legal rights. 
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213608] and investigator or authorized designee, as required by [CONTACT_181015].  
A copy of the Patient Consent Form and the Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language, signed and dated as required by [CONTACT_2371], must 
be provided to the subject.  
If the PIC is obtained the same day the subject begins participating in study -related procedures, it must 
be documented in the subject’s case history that consent was obtained prior to participation in any 
study -related procedures. It is best practice for the informed consent process to be documented in the 
subject’s case history, regardless of circumstance.  
In the event the subject cannot read and/or write, witnessed (impartial third party) patient informed consent will be allowed, provided detailed documentation of the process is recorde d in the subject’s 
case history and the witness signs and dates the patient informed consent. The Consent Form should 
document the method used for communication with the prospective subject and the specific means by 
[CONTACT_181016].  
The Patient Consent Form and Authorization to Use and Disclose Personal Health Information/Research 
Authorization/other privacy language as required by [CONTACT_131476]. Any Medtro nic Field personnel who support the Reveal LINQ ICM insertion procedure must be able to 
review the subject’s original signed and dated Consent Form and verify its completeness prior to proceeding with the insertion. In the event the Medtronic Field personnel identify patient informed 
consent as being incomplete, the study procedure will not be allowed to occur until the consent of the 
subject can be adequately and appropriately obtained.  
When a patient and the principal investigator [INVESTIGATOR_166657],  as required have personally 
signed and dated the Consent Form, the patient is considered a subject enrolled in the study.  
The date the subject signed the Consent Form and data protection authorization must be documented 
in the subject’s medical records. 
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213609] occur within 10 days of 
the quali fying stroke event.  
Subjects will be randomized in a 1:1 fashion to the continuous monitoring arm (Reveal LINQ ICM) or 
control arm (standard of care) using the RDC electronic system. Randomization schedules will be created 
by a statistician  and randomizat ion assignments will be automatically populated on the Randomization 
e-CRF after subject consent and eligibility verification have been entered in RDC. The randomization 
schedule will be stratified by [CONTACT_181017] 1:1 randomization within each stud y site.  
Once subjects are assigned to a study arm (continuous monitoring or control), they are  considered 
randomized.  All randomized subjects  should be encouraged to comply with the Stroke AF study 
procedures until study closure and every effort should be  made to avoid crossover. Statistical analysis 
will be done on an intention to treat basis unless otherwise specified. Therefore, once a subject is 
assigned to an arm, he/she will remain in this arm and all efforts will be made to provide the optimal 
thera py specified per the assigned treatment arm. In case this is clinically or technically not feasible, the 
intention to treat is assured. A per -protocol analysis cohort will also be defined within the statistical 
analysis plan (SAP) and additional supportive  analyses of the objectives may be performed in this cohort.  
8.4. Procedures  and Data Collection  
8.4.1.  Baseline  
The baseline visit can be a standalone visit or can be performed on the same day, but not later than the 
insertion procedure.  
The following information is  required to be collected at the baseline visit:  
• Informed Consent  
• Inclusion/Exclusion Assessment  
• Randomization  
• Subject Demographics  
• Medical History, including but not limited to cardiovascular history, and details about the 
qualifying stroke event (if available) 
• Cardiovascular Medications 
• TOAST Stroke Classification 
• National I nstitute of Health (NIH) Stroke Scale  
• Modified Rankin Scale  
• EQ-5D™  
• Blood Draw  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 30 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  o Five blood tubes (one plasma, three serum and one whole blood) will be collected, 
processed, and sent to the central laboratory for analysis of biomarkers that are 
considered potential predictors of identifying patients who may at high risk for AF.  
• One 6 mL tube of blood will be collected and processed for plasma for B -type 
Natriuretic Peptide (BNP) analysis. The residual from the tube will be kept in 
long-term storage for future analysis.  
• Two 5 mL tubes of blood  will be collected and processed for serum for 
Troponin -I, C-reactive protein (CRP), and thyroid -stimulating hormone (TSH) 
testing. The residuals  from these three tubes will be kept in long -term storage 
for future analysis.  
• One 5 mL tube of blood will be collected, processed for serum and kept in long-
term storage for future analysis.  
• One 4 mL tube of whole blood will be collected for genetic tes ting such as 
genotypi[INVESTIGATOR_180986] (SNP). 
o Specifics regarding the acquisition of these specimens, necessary supplies, and shippi[INVESTIGATOR_180987], under separate cover, will be provided to all study centers by [CONTACT_11378].  
o If a study center does not have the ability to perform the blood draw per the CIP or if 
the patient declines, a study deviation is not required.  
8.4.2.  Reveal LINQ ICM Insertion  
The insertion procedure must occur within 10 days of the qualifying stroke event and aft er 
randomization. The insertion will be performed in accordance with the hospi[INVESTIGATOR_307]’s standard insertion 
practice and in accordance with the Medtronic Reveal LINQ ICM insertion instructions which are found within the Reveal LINQ ICM Clinician manual. The following information is required to be collected at the 
insertion visit: 
• System and Procedure Information  
System and procedure details will be collected including, but not limited to procedure date, device 
serial number, location of insertion procedure, location/orientation of inserted device, antibiotic use, and closure method.  
• Device Programming/Interrogation  
Programming requirements for the Reveal LINQ ICM are outlined in Table 6 below. A full device interrogation will be collected after final programming. Programming changes will be allowed only when clinically necessary. All deviations from the programming g uidelines (regardless of when they 
occur) must be documented on a Study Deviation e-CRF, including the rationale for the deviation.  
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 31 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 3: Reveal LINQ ICM Programming 
Parameter Required Setting  
Reason for Monitoring  Cryptogenic Stroke  
AF Detection Sensitivity  Balanced Sensitivity  
Ectopy Rejection  Aggressive  
AT/AF Recording Threshold  All Epi[INVESTIGATOR_180988]/AF Detection  AF Only  
Wireless Data Priority  Tachy, Pause, Brady  
Tachy Detection  ON 
Brady Detection  ON 
Pause Detection  ON 
 
The subject will be instructed about the use of the Medtronic MyCareLink Monitor and the Patient 
Assistant.  
If the subject does not have a Reveal LINQ ICM device in the body at the conclusion of the procedure, the subject should remain in the study and the follow -up schedule remains unchanged. For these 
patients, CareLink transmissions at 3 and 9 months are not required.  
8.4.3.  Scheduled Follow -up Visits/CareLink Transmissions  
After receiving notice of rando mization assignment, Medtronic will provide the target dates and 
windows for each scheduled visit/CareLink transmission to the site. Should a subject miss a visit/transmission or the visit/transmission fall outside the pre -specified window, a study deviation must 
be reported and the original follow -up schedule maintained for subsequent visits/transmissions.  
Data analyses include follow-up visits/CareLink transmissions, regardless of whether the visit occurs within the window; therefore, a late visit is preferred over a missed visit. Follow -up visit/CareLink 
transmission windows are listed in the Table [ADDRESS_213610] randomization. 
 
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 32 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 4: Follow -up Visit / CareLink Transmission Schedule  
Study Follow -up 
Visit Window  
(Calculated days post randomization)  
Window Start  
 Target  
 Window End  
 
1 Month  23 30 37 
3 Month  
(CareLink Transmission)  76 91 106 
6 Month  168 183 198 
9 Month  
(CareLink Transmission)  259 274 289 
12 Month (1 year)  365 365 421 
18 Month  521 549 577 
24 Month (2 year)  702 730 758 
30 Month  887 915 943 
36 Month (3 year)  1067  1095  1123  
[IP_ADDRESS].  Follow -up Visits  
The following information will be collected at during follow -up visits at 1, 6, and [ADDRESS_213611] -
insertion, and at recurring 6 month intervals after that until study closure:  
• Cardiovascular Medications 
• Modified Rankin Scale (1, 6 and 12 month only)  
• EQ-5D™ (1, 6 and 12 month only)  
• Reveal LINQ Interrogation or remote CareLink transmission (subjects with a Reveal LINQ ICM  
only)  
• AF Assessment  
• Symptom Assessment  
• Stroke/TIA Assessment  
 
Data may be collected remotely for subjects unable to return to the clinic for the follow up visit.  
Patients in the control arm should be monitored for cardiac arrhythmias per the study site standard of 
care. Source documentation (e.g. ECG, Holter, etc.) from any additional cardiac arrhythmia diagnostic 
testing or monitoring which detects AF must be sent to Medtronic.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 33 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  [IP_ADDRESS].  Follow -up Visits /  Remote CareLink Transmissions  
Subjects are required to per form a manual CareLink transmission at 3, and [ADDRESS_213612] to the 
study site. Routine visits or other planned visits are not collected.  
The following information is required to be collected at unscheduled follow -up visits:  
• Reveal LINQ Interrogation (if available, subjects with a Reveal LINQ ICM only)  
• AF Assessment  
• Symptom Assessment  
• Stroke/TIA Assessment  
• Adverse Event e -CRF (if applicable)  
8.4.5.  Stroke/TIA Recurrence 
Following the index event, a subject should be monitored for stroke recurrence. If there is a stroke/TIA 
recurrence, the following data is required to be collected:  
• Details about the stroke event, such as type, size, and location.  
• TOAST stroke classification  
• National Institute of Health (NIH) Stroke Scale  
• Modified Rankin Scale  
• Reveal LINQ Interrogation (if available, subjects with a Reveal LINQ ICM only ) 
• AF Assessment  
• Adverse Event e -CRF  
8.4.6.  System Modification  
A system modification will be reported in the event the Reveal LINQ ICM requires invasive modific ation 
(e.g., explant, replacement, repositioning).  
• If the modification consists of repositioning or replacement, the follow -up schedule for the 
subject will remain unchanged.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 34 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • If the Reveal LINQ ICM is explanted, the subject should continue participation in this study and a 
crossover e -CRF is required. If the subject receives implant of another Medtronic device (IPG, 
ICD or CRT) reference Table 8 for recommended programming parameters for these devices.  The other parameters for these devices are to be programmed based on the investigator’s opi[INVESTIGATOR_1649].  
Table 5: Recommended P rogramming Parameters for Medtronic IPG, ICD or CRT Devices  
Parameter  Recommended Setting  
Atrial preference pacing (APP)  OFF 
Atrial rate stabilization (ARS)  OFF 
Post -mode switch overdrive pacing (PMOP)  OFF 
Atrial Anti -tachycardia pacing (ATP)  OFF 
AT/AF detection and EGM collection  Nominal  
 
The following will be collected in the event of a system modification: 
• Reason for modification  
• System/Procedure Information  
• Pre-modification: device interrogation  
• Post -modification: device interrogation (if modification includes a Medtronic device)  
 
All explanted product should be returned to Medtronic for analysis when permissible by [CONTACT_181018] d 
regulations.  
8.4.7.  Study Exit 
A study exit e -CRF is required for all subjects except in the case of death.  Prior to exiting a subject from 
the study, it is recommended to follow the subject until all ongoing system and/or procedure related 
AEs are resolved or unresolved with no furthe r actions planned.  Following exit, subjects should 
continue to receive standard medical care.  Upon exiting from the study, no further study data will be collected or study visits will occur for the subject.  All data available through the time of the subject’s exit will be used for analysis.  
Subjects are urged to remain in the study as long as possible but may be exited from the study for any of 
the following situations:  
• Subject lost to follow -up 
• Subject did not meet inclusion/exclusion criteria  and not randomized  
• Subject not randomized  
• Subject did not provide consent or data use protection authorization  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 35 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • Subject chooses to withdraw (e.g., consent withdrawal, relocation to another geographic 
location)  
• Investigator deems withdrawal necessary (e.g., med ically justified, inclusion/exclusion criteria 
not met, failure of subject to maintain adequate study compliance)  
• Subject with a Reveal LINQ ICM that has reached end of device life (continuous monitoring patients only)  
• Subject has completed 3 years of fol low-up  
• Study Closure  
The following information is required to be collected at study exit on the study exit e-CRF:  
• Date of exit  
• Reason for exit  
• Reveal LINQ Interrogation (if available, subjects with a Reveal LINQ ICM inserted only)  
• AF Assessment (except in the case of lost to follow -up or death)  
• Stroke/TIA Assessment (except in the case of lost to follow -up or death)  
 
In the case that the subject is determined to be lost to follow -up, details of a minimum of two attempts 
and the method of attempt (e.g., one letter and one phone record or two letters) to contact [CONTACT_181019]. In addition, follow the regulations set forth by [CONTACT_181020].  
8.5. Assessment of Safety  
Timely, accurate, and complete reporting and analysis of safety information for clinical studies are crucial for the protection of subjects. Reporting and analysis of safety data a re mandated by [CONTACT_181021]. Medtronic has established procedures in conformity with worldwide regulatory requirements to ensure appropriate reporting of safety information. This study is conducted in accordance with these procedures and regulations.  
Since the safety reporting requirements and classification systems vary for each regulatory agency, requirements from all geographies are taken into account for the collection and reporting of safety information.  
8.6. Recording Data  
Data will be collected via electronic Case Report Forms (e -CRFs), Reveal LINQ ICM device interrogation 
files, and Medtronic CareLink transmissions. A web -based application tool, Remote Data Capture (RDC) 
will be used for data entry of e-CRFs. The investigator is responsible for the preparation (review and 
signature) of the e-CRF.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213613] in an emergency or in unforeseen situations beyond 
the investigator’s control (e.g. subject failure to attend scheduled follow -up visits, inadvertent loss of 
data due to computer malfunction, inability to perform required procedures due to subject illness). 
For medically justifiable conditions which preempt a subject’s ability to complete a study -required 
procedure, it may be permitted to report only one deviation which will apply to all visits going forward. 
This may also apply for other unforeseen situations (e.g. the subject permanently refuses to complete a study required procedure and the data will not contribute to the primary end point analysis). However, 
prior approval from Medtronic is required for such situations.  
All study deviations must be reported on the Study Deviation e-CRF regardless of whether medically 
justifiable (e.g. crossover), pre -approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect 
the subject in an emergency. The deviation description must be recorded with an explanation for th e 
deviation. In the occurrence of a corrupted device interrogation file, Medtronic may request a deviation to document that a readable interrogation file is unavailable.  
In the event the deviation involves a failure to obtain a subject’s consent, or is mad e to protect the life 
or physical well-being of a subject in an emergency, the deviation must be reported to the Ethics Committee as well as Medtronic within five (5) working days. Reporting of all other study deviations should comply with Ethics Committee policies and/or local laws and must be reported to Medtronic as 
soon as possible upon the site becoming aware of the deviation. Reporting of deviations must comply with Ethics Committee policies, local laws, and/or regulatory agency requirements.  Refer to Investigator Reports, Table 12 for geography -specific deviation reporting requirements and timeframes for reporting 
to Medtronic and/or regulatory bodies.  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying a ny 
additional corrective and/or preventive actions (e.g. amend the Clinical Investigation Plan, conduct 
additional training, terminate the investigation). Repetitive or serious investigator compliance issues 
may result in initiation of a corrective action plan with the investigator and site, and in some cases, necessitate suspending enrollment until the problem is resolved or ultimately terminating the 
investigator's participation in the study. Medtronic will provide site -specific reports to investigators 
summarizing information on deviations that occurred at the investigational site on a periodic basis.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213614] identified below 
are consistent with those outlined in the device manual. There may be other discomforts and risks 
related to the device system and/or this study that are not foreseen at this time.  
9.1. Potential Risks  
Possible risks associated with the Reveal LINQ ICM include but are not limited to the following: 
• Risks associated with a minor surgical procedure  
• Slight risk of infection  
• Sensitivity to the device  
9.2. Potential Benefits  
The Reveal LINQ ICM may offer no benefit. The potential benefits of having the Reveal LINQ ICM include 
more intensive follow -up treatme nt and frequent device transmissions and/or continuous monitoring 
enabling more precise detection of AF. This better precision to detect AF may lead to clinicians having 
better data to quantify AF burden. The information gained from this study could result  in the improved 
detection and management of atrial fibrillation. Additionally, information collected from this study may 
assist in the design of new product(s)/therapy(ies) and/or instructions for use. The System may not offer 
a direct clinical benefit to  study subjects. The information collected from this study may assist in the 
design of new product(s)/therapy(ies) and/or instructions for use.  
9.3. Risk-Benefit Rationale  
The potential risks associated with the Reveal LINQ ICM were identified and have been su ccessfully 
mitigated. Any potential risks associated with this study are further minimized by [CONTACT_181022].  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213615] interrogate the Reveal LINQ ICM and assess for any 
adverse events.  
• Risks associated with a minor surgical procedure  
• Slight risk of infection  
• Sensitivity to the device  
10. Adverse Event s and Device Deficiencies  
All reported Adverse Events (AEs) must be followed until resolved, ongoing without further actions to be 
taken, the subject exits the study or until study closure, whichever occurs first. In the event that a subject is exited from the study prior to study closure, all efforts should be made to continue following 
the subject until all ongoing AEs are resolved or they are ongoing without further actions to be taken.  
10.1.  Adverse Event Assessment  
10.1.1.  Adverse Events  
All Reveal LINQ ICM system/component -related, Reveal LINQ ICM procedure related, cardiovascular 
related AEs, and all serious adverse events leading to death will be collected throughout the study 
duration, starting at the time of signing the consent form.  
Reporting of these events to Medtronic will occur on an Adverse Event (AE) e -CRF, including a 
description of AE, date of onset of AE , date of awareness of site, treatment, resolution, assessment of 
both the seriousness and the relatedness to the investigational device. Each AE must be recorded on a separate AE Form. Subject deaths are also required to be reported. Refer to Section 10.[ADDRESS_213616] 
Death collection and reporting requirements.  
Documented pre-existing conditions are not considered AEs unless the nature or severity of the condition has worsened. Additionally, detected arrhythmias (including AF) for which no action is taken are not reportable AEs. Unavoidable Adverse Events, listed in Table [ADDRESS_213617]-insertion.  
For AEs that require immediate reporting (see Table 11), initial reporting may be done by [CONTACT_648], fax, or 
on the e-CRF completing as much information as possible, with missing or follow -up information 
provided as soon as it becomes available. The AE e -CRF must be completed as soon as possible.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 39 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  10.1.2.  Device Deficiencies  
Device defic iency (DD) information will be collected throughout the study and reported to Medtronic. 
Note that device deficiencies that result in an adverse device effect (ADE) to the subject should be 
captured as an Adverse Event only.  
10.1.3.  Processing Updates and Resolution 
For any changes in status of a previously reported AE (i.e. change in actions taken, change in outcome, change in relatedness), information needs to be updated on or added to the original AE e-CRF. All 
reported adverse events must be followed until the adverse event has been resolved, is unresolved with 
no further actions planned, the subject exits the study or until study closure, whichever occurs first.  
In the event that a subject is exited from the study prior to study closure, all efforts should be made to 
continue following the subject until all unresolved procedure or system related adverse events, as 
classified by [CONTACT_093], are resolved or they are unresolved with no further actions planned.  
At the time of study exit, all AEs with an outcome of “Unresolved, further actions or treatment planned” 
must be reviewed and an update to the original AE e- CRF must be reported. At a minimum, if there are 
no changes to the description, relatedness, test and procedures or actions taken, the outcome mus t be 
updated to reflect “Unresolved at time of study closure.”  
10.2.  Definitions/Classifications  
10.2.1. Adverse Event and Device Deficiency Definitions  
Where the definition indicates “device”, it refers to any device used in the study.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 40 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 6: Adverse Event Definitions  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 41 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  General  
Adverse Event (AE)  
(Adapted from ISO [ZIP_CODE]:2011, 3.2)  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in 
subjects, users or other persons, whether or not related to the investigational medical device  
 
NOTE 1: This definition includes events related to the investigational 
medical device or the comparator.  NOTE 2: This definition includes events related to the procedures involved.  
 
Adverse Device Effect (ADE)  
(ISO [ZIP_CODE]:2011, 3.1)  Adverse event related to the use of an investigational medical device  
 NOTE 1 : This definition includes adverse events resulting from 
insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  
 
NOTE 2: This definition includes any event resulting from an error use or 
from intentional misuse of the investigational medical device.  
 
Device Deficiency (DD)  
(ISO [ZIP_CODE]:2011, 3.15)  
 Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance.  
 NOTE: Device deficiencies include malfunctions, use errors and inadequate labeling  
 
Relatedness  
Reveal LINQ ICM  Procedure Related  
 An adverse event that occurs that is directly related to the implantation 
or modification of the Reveal LINQ system.  
Reveal LINQ ICM  System Related  
 An adverse event that results from the presence or performance 
(intended or otherwise) of any component of the system (including: 
Reveal LINQ ICM, Programmer, Patient Assistant, and MyCareLink 
Patient Monitor).  
 
Cardiovascular Related  An adverse event relating to the heart and the blood vessels or the 
circulation.  
Seriousness  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 42 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Complication   An adverse event that results in death, involves any termination of 
significant device function, or requires invasive intervention.  
 
Non -invasive: when applied to a diagnostic device or procedure, means 
one that does not by [CONTACT_180996]:  
• Penetrate or pi[INVESTIGATOR_180989], the ocular cavity or the urethra or  
• Enter the ear beyond the external auditory canal, the nose beyond the nares, the mouth beyond the pharynx, the anal canal beyond the rectum, or the vagina beyond the cervical os
 
 
For purposes of this part, blood sampling that involves simple 
venipuncture is considered non- invasive, and the use of surplus samples 
of body fluid or tissue that are left over from samples taken for non-
investigational purposes is also considered non -invasive.  
 
Observation  Any adverse event that is not a complication.  
 Note 1 : Only system or procedure related AEs will be classified as  
Complication or Observation. 
 
Serious Adverse Event (SAE)  
(Adapted from ISO [ZIP_CODE]:2011, 3.37)  
 Adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject, that either resulted in 
5. a life -threatening illness or injury, or  
6. a permanent impairment of a body structure or a body function, or  
7. in-patient or prolonged hospi[INVESTIGATOR_059], or  
8. medical or surgical intervention to prevent life -threatening 
illness or injury or permanent impairment to a body structure or a body function,  
c) led to fetal distress, fetal death or a congenital abnormality or birth 
defect  
 
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_10396], without serious deterioration in health, is not considered a serious adverse event.  
  
Other  
Hospi[INVESTIGATOR_059]  A therapeutic inpatient hospi[INVESTIGATOR_059] (excludes outpatient and 
emergency room visits) lasting greater than or equal to 24 hours. 
Stroke  
 Hemorrhagic or Ischemic stroke with rapid onset of a focal or global 
neurological deficit or other neurological signs/symptoms consistent 
with stroke.  
Stroke Diagnosis  Diagnosis will be determined by [CONTACT_779]’s neurologist clinical evaluation 
and include clinical signs and symptoms consistent with focal or global 
neurological deficit in addition to one or more of the following:  
• Neuroimaging procedure (CT, MR, or cerebral angiogram)  
• Lumbar Puncture (i.e. subarachnoid hemorrhage)  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 43 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Transient Ischemic Attack (TIA)  New focal neurological deficit with rapid symptom resolution (usually 1 
– 2 hours), always within 24 hours without tissue injury (based on 
neuroimaging).  
Unavoidable Adverse Event  An Adverse Event inherent to a surgical procedure that is expected to 
occur in all subjects for a projected duration according to the 
Investigator’s op inion, including, but not limited to:  
 
Event Description  Timeframe 
(hours) from the 
Surgical 
Procedure  
Anesthesia related nausea / vomiting  24 
Low-grade fever (<100°F or 37.8°C)  48 
Pocket site / Incisional pain  72 
Mild to moderate bruising / ecchymosis  168 
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
Shoulder pain/discomfort/stiffness related to 
shoulder immobilization during procedure  72 
 
10.2.2.  Adverse Events and Deficiency Classification 
All reported AEs and DDs will be reviewed by a Medtronic representative. AEs will be classified according 
to the definitions provided.  
Upon receipt of AEs at Medtronic, a Medtronic representative will review the AE/DD for completeness 
and accuracy and whe n necessary will request clarification and/or additional information from the 
Investigator. Medtronic will utilize MedDRA, the Medical Dictionary for Regulatory Activities, to assign a MedDRA term for each adverse event based on the information provided by  [CONTACT_093].  
Regulatory reporting of AEs and DDs will be completed according to local regulatory requirements. Refer to Table [ADDRESS_213618] a clinical study representative immediately (refer to the 
study contact [CONTACT_181023]’s study documents binder/investigator site file or refer to the contact [CONTACT_131484]).  
Adverse Events and Deaths will be classified according to the standard definitions as outlined belo w:  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 44 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 7: Adverse Event Classification Responsibilities 
What is classified?  Who classifies?  Classification Parameters  
Relatedness  
 Investigator  • Procedure Related  
• System Related  
Sponsor  • Procedure Related  
• System Related  
• Cardiovascular Related  
Seriousness  Investigator  SAE 
Sponsor  SAE, Complication or Observation (for all system or procedure 
related adverse events)  
Diagnosis  Investigator  Based on presenting signs and symptoms and other supporting 
data  
Sponsor  MedDRA term assigned based on the data provided by 
[CONTACT_54437], Non -sudden Cardiac, Non -Cardiac, Unknown  
 
An independent Clinical Events Committee (CEC) will at minimum conduct a medical review of all 
endpoint related events for subjects participating in the study.  Additionally, the CEC will provide an adjudication of the death classification for all reported deaths.  
10.3.  Reporting of Adverse Events  
Regulatory reporting of AEs/DDs will be completed according to local regulatory requirements. Refer to Table of Adverse Event Reporting Requirements for a list of required investigator reporting 
requirements and timeframes, and of required Medtronic reporting requirements and timeframes. 
 
The investigator is requ ired to report all SAEs to Medtronic immediately, and to the Ethics Committee 
per local requirements. Medtronic is also required to report these events to the local regulatory 
authority based on their requirements. It is the responsibility of the investigator to abide by [CONTACT_54438]/DD reporting requirements stipulated by [CONTACT_181024].  
For AEs/DDs that require immediate reporting, initial reporting may be done by [CONTACT_181025].  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 45 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 8: AE Reporting Requirements  
Serious Adverse Events (SAEs)  
Investigator submit to:  
Medtronic  Submit in a timely manner after the investigator first learns of the event.  
EC/IRB/MEC  Submit to EC/IRB/MEC per local reporting requirement.  
Regulatory 
authorities  Submit to regulatory authority per local reporting requirement.  
Sponsor submit to:  
Regulatory 
authorities  Submit to regulatory authority per local reporting requirement.  
EC/IRB/MEC  Submit to EC/IRB/MEC per local reporting requirement.  
All other reportable Adverse Events  
(System, Procedure, Cardiovascular -Related)  
Investigator submit to:  
Medtronic  Submit in a timely manner after the investigator first learns of the event.  
EC/IRB/MEC  Submit to EC/IRB/MEC per local reporting requirement.  
Regulatory 
authorities  Submit to regulatory authority per local reporting requirement.  
Sponsor submit to:  
Regulatory 
authorities  Submit to regulatory authority per local reporting requirement.  
EC/IRB/MEC  Submit to EC/IRB/MEC per local reporting requirement.  
Device Deficiencies  
Investigator submit to:  
Medtronic  Submit in a timely manner after the investigator first learns of the event.  
EC/IRB/MEC  Submit to EC/IRB/MEC per local reporting requirement.  
Regulatory 
authorities  Submit to regulatory authority per local reporting requirement.  
 
 
10.3.1.  Subject Death  
[IP_ADDRESS].  Death D ata Collection 
All subject deaths must be reported by [CONTACT_181026] e-CRF as soon as 
possible after the investigator first learns of the death.  The AE leading to death must be reported and 
will document the death as the outcome. 
For subjects with a Reveal LINQ ICM  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213619]’s death, the inserted device should be explanted and returned to Medtronic for 
analysis whenever possible. Local laws and procedures must be followed where applicable.  
System Interrogation Data Recommendations:  
• After the subject has died but prior to explant, the device shall be interrogated and a full summary interrogation (Interrogate All) performed when possible. 
If the device is not interrogated, an explanation must be entered on the AE form. If any system component is returned to Medtronic, internal return product reporting systems may be used to gather additional information about the returned device/component.  
 
A copy of the death certificate, if available and allowed by [CONTACT_54443]/local law, should be sent to the 
Medtronic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary report 
and all relevant hospi[INVESTIGATOR_54380], if available. If an autopsy is conducted, the autopsy report should also be sent to the Medtronic clin ical study team if 
available and allowed by [CONTACT_54443]/local law. When the death occurs at a remote site, it is the investigative 
site’s responsibility to attempt retrieval of information about the death. In summary, the following data 
will be collected:  
• Date o f death  
• Detailed description of death  
• Cause of death  
• Relatedness to system and/or procedure (subjects with Reveal LINQ inserted)  
• Device interrogation (if available, subjects with a Reveal LINQ ICM) 
• Death summary/hospi[INVESTIGATOR_1097] (if available and allowed by [CONTACT_54443]/local law)  
• Autopsy report (if available and allowed by [CONTACT_54443]/local law)  
• Death certificate (if available and/or allowed by [CONTACT_54443]/local law)  
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 47 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  [IP_ADDRESS].  Death Classification and Reporting  
Sufficient information will be required in order to properly classify the subject’s death. The Investigator 
shall classify each subject death per the following definitions:  
Table 9: Subject Death Classification 
Classification  Definition  
Cardiac Death  A death directly related to the electrical or mechanical dysfunction of the heart  
Sudden Cardiac Death (SCD)  Natural death due to cardiac causes, indicated by [CONTACT_181027]; preexisting heart disease may have been 
known to be  present, but the time and mode of death are unexpected. If time of onset 
cannot be determined, SCD will alternatively be defined as any unexpected cardiac death occurring out of the hospi[INVESTIGATOR_54381]. 
Non -sudden Cardiac  Death  All cardiac deaths that are not classified as sudden deaths, including all cardiac deaths 
of hospi[INVESTIGATOR_54382].  
Non -cardiac Death  A death not classified as a cardiac death  
Unknown  There is insufficient or inadequate information to classify the death.  
 
The Clinical Events Committee (CEC) will review deaths and provide a final adjudication of the primary 
cause of death and death classification.  
Regulatory reporting of Subject Deaths will be completed according to local regulatory requirements. 
Refer to Table [ADDRESS_213620]’s participation in a clinical study.  
All devices used in the study are market -released, product complaint reporting is applicable. This 
includes when an AE is related to a market-released device during the study.  The reporting of product 
complaints is not part of the clinical study and should be done in addition to the AE reporting 
requirements.  Refer to local regulations for reporting requirements. 
Product Complaint: Any written, electronic or oral communication that alleges deficiencies related to 
the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that 
has been placed on the market.  
It is the res ponsibility of the investigator to report all product complaint(s) associated with a medical 
device distributed by [CONTACT_13735], regardless whether they are related to intended use, misuse or abuse 
of the product. Reporting must be done immediately and via th e regular channels for market-released 
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213621] Operating Procedures.  
Medtronic will notify the regulatory authorities (e.g. Competent Authority) as applicable for the 
following incidents immediately upon learning of them:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, as well 
as any inadequacy in the labeling or instructions for use which led or might have led t o the 
death or serious deterioration in the state of health of a patient, user, or other person.  
• Any technical or medical reason resulting in withdrawal of a device from the market by [CONTACT_3455]. 
• A serious deterioration in the state of heath includes : 
o Life-threatening illness or injury  
o Permanent impairment of a body function or permanent damage to a body structure  
o In-patient or prolonged hospi[INVESTIGATOR_059]  
o Medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function  
o Fetal distress, fetal death or a congenital abnormality or birth defect  
11. Data Review Committees  
The Stroke AF study will utilize a Steering Committee for study design and oversite, a CEC for the 
assessment  of Adverse Events and recurrent stroke/TIA data, an Endpoint Adjudication Committee (the 
CEC may serve as the EAC) for an independent review of endpoint (AF) and a Publication Committee to manage study publications. 
Committee membership rosters will be ma intained at Medtronic and will be made available upon 
request  
11.1.  Clinical Events Committee (CEC) Review  
At regular intervals, an independent Clinical Events Committee (CEC) will at minimum conduct a medical 
review (adjudicate) of reported arrhythmias including AF epi[INVESTIGATOR_1841]/events as well as reported strokes/TIAs and deaths for subjects participating in the st udy.  
The CEC will consist of a minimum of three (3) non -Medtronic employed physicians that are not 
participating investigators for the study, including a CEC chairperson. At least three CEC members must adjudicate, at a minimum, all deaths and endpoint re lated events.  All other AEs may be adjudicated by 
[CONTACT_181028].  
Medtronic personnel may facilitate and participate in a CEC meeting but will be non -voting members.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 49 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  For adverse events and deaths reviewed by [CONTACT_15741], Medtronic will provide the CEC with the 
Investigator’s description and classification. The CEC is responsible for reviewing the Investigator’s 
assessment and supportive documentation (when available), reviewing applicable definitions, and 
determining final classifications for all adjudication parameters. Additionally, the CEC will provide an adjudication of the death classification for all reported deaths including primary cause of death.  
If the CEC disagrees with the investigator’s classification of the event, the rationale will be provided to 
the investigator. If the investigator agrees with the CEC’s adjudication, the case report form 
documenting the AE will be updated accordingly.  
If the investigator does not agree with the CEC’s adjudication classification, both determinations will be provided within the final report; however the CEC’s adjudication will be used for data analysis. The 
disagreement will also be included in reporting to ethic committees and regulatory authorities, if 
required. 
12. Statistical Design and M ethods  
Medtronic employees or designees will perform all statistical analyses. Additionally, a separate 
Statistical Analysis Plan (SAP) will be developed to further describe statistical methods, pre -specified 
data handling rules, and pre-specified analyses  that will be included in study reports. Any change to the 
data analysis methods described in the CIP will require an amendment only if it changes a principal feature of the CIP. Any other change to the data analysis methods described in the CIP, and the 
justification for making the change, will be described in the clinical study report. Additional exploratory 
analyses of the data may be conducted as deemed appropriate. Missing data will not contribute to the 
objectives unless specified otherwise within the  analysis methods.  
The study has been powered for the primary objective (see sample size determination for the primary 
objective below), to be evaluated after [ADDRESS_213622] been completed. The primary objective data and applicable ancillary o bjective data will be provided in a 12 month report. Secondary 
objective data, and remaining ancillary objective data will be provided in a final report. Ancillary objects are considered exploratory. There will be no correction for multiple testing. Intent -to-treat principles 
will be used for analyzing each of objectives unless otherwise specified.  
12.1.  Primary Objective  
The primary objective is to compare the incidence rate of AF through 12 months between the 
continuous monitoring arm vs control arm in subjects  with a recent ischemic stroke of presumed known 
origin.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 50 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  i. Hypothesis  
H0:   h C(t) = h T(t) for t ≤ 12 months  
• HA:   h C(t) ≠ h T(t) for t ≤ 12 months  
• where h T(t) and h C(t) are the hazard functions of first detected and adjudicated AF at time 
t for subjects with and without the Reveal LINQ diagnostics for AF, respectively. 
ii. Endpoint Definition  
AF will be defined as an AF event lasting more than [ADDRESS_213623] rate of AF is unknown in this population. Data from the CRYSTAL AF study and Rabinstein et al (2013) has been used to estimate the 12 month incidence rate of AF in 
patients with an ischemic stroke of presumed known origin.  
The incidence rate of AF through 12 -months was 12.4% in the continuous monitoring arm in 
the CRYSTAL  AF study which was conducted in patients with a cryptogenic stroke.  
 
Rabinstein et al (2013) used prolonged ambulatory cardiac monitoring to assess the incidence 
rate of paroxysmal AF through 3 weeks in patients with a cryptogenic stroke and patient with  a 
stroke of presumed known cause. The incidence rate of paroxysmal AF through 3 -weeks was 
25% in the patients with a cryptogenic stroke and 14% in patients with an ischemic stroke of 
presumed known origin.  
 
The above incidence rates were used to estimate the [ADDRESS_213624] the AF incidence rate to be lower 
in patients with an ischemic stroke of presumed known origin when compared to the incidence rate in patients with a cry ptogenic stroke. Consequently, an AF incidence rate of 8% 
through 12 months is expected in our continuous monitoring arm. An AF incidence rate of 2% 
through [ADDRESS_213625] of care treatment includes more rhythm monitoring then it did during the time of the CRYSTAL AF study.  
 The objective of the study is to compare the incidence rate of AF through 12 months between the continuous monitoring arm vs control arm in subjects with a recent ischemic stroke of presumed known origin.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 51 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  v. Sample Size Determination  
• A total of [ADDRESS_213626] rates are different 
between the two arms. Approximately 496 subjects will be enrolled. Assuming 2% attrition 
from enrollment to randomization, approximately [ADDRESS_213627].  Withdrawn subjects will not be replaced.  
 
• The assumptions used for the calculations were:  
• Two -sided log -rank test  
• Alpha = 0.05  
• 85% power 
• Annual Attrition rate = 10%  
• Annual Crossover rate = 5% 
• Follow-up Time = 1 year  
• Event-free one -year survival rate of 92% in the continuous monitoring arm  
• Event-free one -year survival rate of 98% in the control arm (hazard ratio of 4.13)  
The procedure “Logrank tests (Lakatos) using proportion surviving” in PASS [ADDRESS_213628]’s inserted/implanted device or from external monitoring will be adjudicated by [CONTACT_181029]. Only first detected and adjudicated AF epi[INVESTIGATOR_42988] 12 -months 
(365 days) will be included for analysis. Each subject’s time to first detected and adjudicated AF will be defined as the time from randomization date to the date of first documented AF (i.e. the date of event per Reveal LINQ ICM, ECG, etc) to meet the primary endpoint definition, and Kaplan-Meier curves will be generated for each randomization arm. Subjects who have not experienced an AF endpoint through 12 months will be censored at:  
• their point of last contact, usable Reveal  LINQ ICM interrogation or CareLink transmission if they occur before 12 months, whichever is later or  
• [ADDRESS_213629] will be performed to compare the rates between arms. 
In addition to the analysis on the full population, subgroup analysis for subjects with small vessel disease stroke and large vessel cervical or intracranial a therosclerosis stroke will be 
presented.  
vii. Determination of Patients/Data for Analysis  
• All randomized subjects will be included in the analysis.   
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 52 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
   
12.2.  Secondary Objective  
To compare the incidence rates of AF through the duration of study follow -up between study arms  
i. Hypothesis  
H0:   h C(t) = h T(t) for t > 0 months 
• HA:   h C(t) ≠ h T(t) for t > 0 months 
• where h T(t) and h C(t) are the hazard functions of first detected and adjudicated AF at time 
t for subjects with and without the Reveal LINQ diagnostics for AF, respectively.  
ii. Endpoint Definition  
Adjudicated AF event as described in section 13.1.ii.  
iii. Performance Requirements  
This secondary objective will be tested in a hierarchical fashion. This means that if the primary 
objective is met, then th is secondary objective will be tested.  
The null hypothesis will be rejected if the two -sided log-rank test p -value is less than 0.05.  
iv. Sample Size Determination  
• A two -sided log -rank test with the assumptions below achieves 100% power to test the 
secondary objective.  
 
• The assumptions used for the calculations were:  
o Two -sided log -rank test  
o Alpha = 0.05  
o Annual Attrition rate = 10%  
o Annual Crossover rate = 5% 
o Accrual Time = 2 years  
o Follow-up Time = 3 years  
o Event-free survival rate of 80% in the continuous monitoring arm  
o Event-free survival rate of 97% in the control arm (hazard ratio of 7.33)  
o Number of subjects randomized = 486  
The procedure “Logrank tests (Lakatos) using proportion surviving” in PASS [ADDRESS_213630]’s time to first detected and adjudicated AF will be defined as in section 13.1, and 
Kaplan-Meier curves will be generated for each randomization arm. Subjects who have not 
experienced an AF endpoint through the duration of the study follow -up will be censored at 
their point of last contact, usable Reveal LINQ ICM interrogation or CareLink transmission, whichever is later.  A two -sided log-rank test will be performed to compare the rates between 
arms.  
 
In addition to the analysis on the full population, subgroup analysis for subjects with small 
vessel disease stroke and large vessel cervical or intracranial atherosclerosis  stroke will be 
presented.  
vi. Determination of Patients/Data for Analysis  
All randomized subjects will be included in the analysis.  
13. Ethics  
13.1.  Statement(s) of Compliance  
This study will be conducted in compliance with international ethical and scientific quality standards, 
known as good clinical practice (GCP). GCP includes review and approval by [CONTACT_54448]/IRB/MEC before initiating a study, continuing review of an ongoing study by [CONTACT_181030] a subject before initiating the study.  
The principles of the Declaration of Helsinki have been implemented through the pa tient informed 
consent (IC) process, Ethics Board/IRB/MEC approval, study training, clinical trial registration, preclinical 
testing, risk-benefit assessment and publication policy.  
This study will be conducted in compliance with [ADDRESS_213631] (FDAAA) and Declaration of Helsinki on http://clinicaltrials.gov (PL 110 -
85, Section 810(a)). 
Approval of the CIP is required from the following groups prior to any study procedures at a study site:  
• Medtronic  
• An independent medical ethics committee or institutional review board.  
 
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213632] therefore 
be allowed access to the subjects’ case histories (clinic and hospi[INVESTIGATOR_1097], and other source data/documentation) upon request as per the Subject Informed Consent, Resear ch Authorization 
(where applicable) and Clinical Trial Agreement.  The principal investigator [INVESTIGATOR_131437].   
14.1.1.  
Monitoring Visits  
Frequency of monitoring visits may be based upon subject enrollment, duration of the study, study compliance, number of adverse events, number of deviations, findings from previous monitoring visits 
and any suspected inconsistency in data that requires investigation. Regulatory documents may be 
reviewed at each study site. Monitoring for t he study, including site qualification visits, site initiation 
visits, interim monitoring visits, and closeout visits, will be done in accordance to the study -specific 
monitoring plan. Monitoring will be planned either at the study site, via telephone, or electronically to assure compliance with the study protocol. Site activation, periodic visits and study closure visits will 
occur either on -site, via email or via telephone.  
Monitoring visits may be conducted periodically to assess site study progress, the  investigator’s 
adherence to the CIP, regulatory compliance including but not limited to IRB/Ethics Committee approval 
and review of the study, maintenance of records and reports, and review of source documents against 
subject e-CRFs. Monitors review site regulatory and study compliance by [CONTACT_54450] -
compliance and communicating those findings along with recommendations for preventative/corrective actions to site personnel.  Monitors may work with study personnel to determine appropriate co rrective 
action recommendations and to identify trends within the study or at a particular site.  
14.2.  Data Management  
Data will be collected using an electronic data management system for clinical studies.  e -CRF data will 
be stored in a secure, password -prote cted database which will be backed up nightly.  Data will be 
reviewed using programmed and manual data checks.  Data queries will be made available to sites for 
resolution.  Study management reports may be generated to assess data quality and study progress.  At 
the end of the study, the data will be frozen and will be retained indefinitely by [CONTACT_13735].  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213633] party designated by 
[CONTACT_54452] a key coded form, unless it’s impossible to make it anonymous, for instance, where the 
patient’s name [CONTACT_131514], such as fluoroscopy images.     
Procedures in the CIP require source documentation.  Source documentation will be maintained at the site. Source documents, which may include worksheets, patient medical records, programmer printouts, 
and interrogation files, must be created and maintained by [CONTACT_2727] t eam.  
The data reported on the e-CRFs shall be derived from source documents and be consistent with these 
source documents, and any discrepancies shall be explained in writing.  
Device data from Reveal LINQ ICM interrogations and CareLink transmissions wil l be uploaded to secure 
servers.  Save -to-media data collected at office visits will be sent to Medtronic.  Upon receipt, device 
data will be maintained with databases and retrieved for analysis and reporting. 
14.3.  Direct Access to Source Data/Documents  
The sponsor or a regulatory authority may audit or inspect the study site to evaluate the conduct of the study. The clinical investigator(s)/institution(s) shall allow study related monitoring, audits, Ethics Board 
review and regulatory inspection by [CONTACT_1541] d irect access to source data/documents.  
14.4.  Confidentiality  
All records and other information about subjects participating in this study will be treated as 
confidential. The identity of a subject will never be disclosed in the event that study data are publishe d. 
14.5.  Liability  
Warranty information is provided in the product packaging for the Reveal LINQ ICM and additional copi[INVESTIGATOR_54398].  
14.6.  CIP Amendments  
Approval of the CIP is required from the following groups prior to any study procedures at a study site:  
• Medtronic  
• An independent medical ethics committee or institutional review board.  
 
Similarly, approval of subsequent revisions to the CIP is required at each study site from the above-
mentioned groups prior to implementation of the revised CIP at that site.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213634] Retention 
14.7.1.  Investigator Records  
The investigator is responsible for the preparation and retention of the records cited below. All of the 
below records, with the exception of case history records and case report forms, should be kept in the 
Investigator Site File (i.e., the study binder provided to the investigator) or Subject Study Binder. E-CRFs must be maintained and signed electronically within the electronic data capture system during the 
study. The following records are subject to inspection and must be retained for a period of two years (or 
longer as local law or hospi[INVESTIGATOR_54387]) after the date on which the investigation is terminated.  
• All correspondence between the IRB/MEC, sponsor, monitor, and the investigator that pertains 
to the investigation, including required reports.  
• Subject’s case history records, including:  
o Signed and dated informed consent form persona lly signed by [CONTACT_1130]  
o Observations of adverse events/adverse device effects/device deficiencies  
o Medical history 
o Insertion and follow -up data  
o Documentation of the dates and rationale for any deviation from the protocol  
• List of investigation sites  
• All approved versions of the CIP, and PIC.  
• Signed and dated Clinical Trial Agreement.  
• Current curriculum vitae of principal investigators.  
• Documentation of delegated tasks.  
• IRB/MEC approval documentation. Written information that the investigator or other study staff, when member of the IRB/MEC, did not participate in the approval process. Approval 
documentation must include the Ethics Board composition, where required per local law.   
• Study training records for site staff.  
• Final Study Report including the statistical analysis.  
  
14.7.2.  Investigator Reports 
The investigator is responsible for the preparation (review and signature) and submission to the sponsor 
of all case report forms, adverse events and adverse device effects (reported per the country -specific 
collection requirements), device deficiencies, deaths, and any deviations from the clinical investigation 
plan.  If any action is taken by [CONTACT_2717]/MEC with respect to this clinical study, copi[INVESTIGATOR_180990]  
  
[ADDRESS_213635] to inspection 
and to the retention requirements as described above for investigator records.  
Safety data investigator reporting requirements are listed in Section 10 of the Adverse Eve nt section. 
The investigator shall prepare and submit in a complete, accurate and timely manner the reports listed 
in this section.  
 
Table 10: Investigator R eports per Medtronic Requirements  
Report  Submit to  Description/Constraints  
Withdrawal of IRB/MEC 
approval  Sponsor and Relevant Authorities  The investigator must report a withdrawal of approval by [CONTACT_54455]/MEC of the investigator’s part of the investigation 
within 5 working days.  
Study Deviations  Sponsor and  
IRB/MEC  Any deviation from the clinical investigational plan shall be 
recorded together with the explanation of the deviation. 
Notice of deviations from the CIP to protect the life or physical well-being of a subject in an eme
rgency shall be given as soon as 
possible, but no later than 5 working days after the emergency occurred.  Except in such emergency, prior approval is required 
for changes in the plan or deviations.  
Final Report  IRBs/MECs and  
Relevant Authorities  This r eport must be submitted within 3 months of study 
completion or termination.  
14.7.3.  Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records: 
• All correspondence which pertains to the investigation 
• Signed Investigator Trial Agreements and current curriculum vitae of principal investigator [INVESTIGATOR_180991]  
• All approved informed consent templates, and other information provided to the subjects and 
advertisements, including translations  
• Copi[INVESTIGATOR_180992] B/MEC approval letters and relevant IRB/MEC correspondence and IRB/MEC 
voting list/roster/letter of assurance  
• Names of the institutions in which the clinical study will be conducted  
• Names/contact [CONTACT_54459]  
• Statistical analyses and underlying su pporting data  
• Final report of the clinical study  
• The Clinical Investigation Plan 
• Study training records for site personnel and Medtronic personnel involved in the study  
• Any other records that local regulatory agencies require to be maintained.  
Stroke AF Clinical Investigation Plan  
  
[ADDRESS_213636] of reviewing IRB/MEC, regulatory agency or FDA, provide accurate , complete and current information about any 
aspect of the investigation. Safety data Medtronic reporting requirements are listed in Section 10 of the Adverse Event section.  
Table 11: Sponsor Reports  
Report  Submit to  Description/Co nstraints 
Premature termination 
or suspension of the clinical investigation  Investigators  
IRB/MEC  
Relevant authorities  
Head of the Institution  Provide prompt notification of termination or suspension and 
reason(s).  
Final report  Investigators,  
IRB/MEC,  
 A final report will be submitted to the investigators, and 
IRBs/MECs within six months after completion or termination of 
this study.   
Study deviation  Investigators  Site specific study deviations will be submitted to investigators 
periodically.   
 
Medtronic records and reports will be maintained in a password-protected document management 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic during the course of this study.  
After closure of the study Medtronic will archive records and reports indefinitely.  
14.8.  Publication and Use of Information 
Publications from the Stroke AF study will be handled according to Cardi ac Rhythm Heart Failure 
Standard Operating Procedures and as indicated in the Clinical Trial Agreement. 
14.8.1.  Publication Committee  
Medtronic may form the Stroke AF Publication Committee from study investigators.  Medtronic 
personnel may serve as members of the committee.  This committee will manage study publications 
with the goal of publishing findings from the data.  The Publication  Committee will develop the final 
Publication Plan as a separate document.   
The Publication Committee’s role is to: 1) manage elements addressed in the publication plan as 
outlined in this appendix, 2) develop the final Publication Plan under separate cover, 3) execute the 
Publication Plan, 4) oversee the publication of primary and ancillary study results, 5) review and 
prioritize publication proposals, 6) provide input on publication content, and 7) determine authorship.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 59 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  In addition, the committee will apply and reinforce the authorship guidelines set forth in the Publication 
Plan.   
Membership in the Publication Committee does not guarantee authorship.  The committee will meet at 
regular intervals, as needed.  
14.8.2.  Management of Primary, Secondary and Ancillary Publications  
The Publication Committee reviews, prioritizes, and manages all publications including primary, 
secondary and ancillary publications.  Primary and secondary publications are those that address analyses of any or all primary objectives or sec ondary objectives, respectively, as specified in the Clinical 
Investigation Plan.  
An ancillary publication is any publication that does not address the study objectives identified in the 
Clinical Investigation Plan.  They include publications proposed and  developed by [CONTACT_181031], clinicians participating in this clinical study, and clinicians not participating in 
this clinical study.  The committee will work with Medtronic to ensure that requests do not present 
conflicts with o ther proposals, are not duplicative, and to determine which ancillary publication 
proposals, if any, will be supported.   
The committee may decide that no publications, including abstracts, will be published prior to the end of the study or with individual  site data.  Requests for publications on study objectives utilizing subset data 
(e.g., regional) will be evaluated for scientific validity and the ability of Medtronic to provide resources.   
14.8.3.  
Criteria for Determining Authorship  
Publications will adhere to  authorship criteria defined by [CONTACT_65646] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, www.icmje.org).  Individual authorship criteria defined by [CONTACT_181032] e will be 
followed when it differs from ICMJE criteria.  
Authors, including Medtronic personnel, must at a minimum meet all of the conditions below:  
• Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of  data  
• Drafting the article or revising it critically for important intellectual content  
• Final approval of the version to be published  
Decisions regarding authorship and contributor -ship will be made by [CONTACT_942]. The selected 
authors will be responsible for drafting the publication. All selected authors must fulfill the authorship 
conditions stated above to be listed as authors, and all contributors who fulfill the conditions must be 
listed as authors.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 60 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  All investigators not listed as co -authors will be acknowledged as the “Medtronic Stroke AF Clinical Study 
Investigators” and will be individually listed according to the guidelines of the applicable scientific 
journal when possible and affiliation. Any other contributors will be acknowledged by [CONTACT_131504].  
14.8.4.  Transparency  
Transparency of study results will be maintained by [CONTACT_54465]:  
• a final report, describing the results of all objectives and analysis, will be distributed to all investigators, MECs and Competent  Authorities of participating countries when required by [CONTACT_49762] 
• registering and posting the study results on ClinicalTrials.gov based on the posting rules stipulated  
• submitting for publication the primary study results after the study ends  
• disclosing conflicts of interest of the co -authors of publications according to the policies set 
forth by [CONTACT_54466]  
• making an individual sites study data accessible to the corresponding investigator after the completion of the study,  if requested  
14.9.  Suspension or Early Termination 
14.9.1.  Planned Study Closure  
Study Closure is a process initiated by [CONTACT_57661] a study closure letter. Study closure is defined as closure of a clinical study that occurs when Medtronic and/or regulatory requirements have been 
satisfied per the Clinical Investigation Plan and/or by a decision by [CONTACT_131488]), 
whichever occurs first. The study closure process is complete upon distribution of the Final Report or 
after final payments, whichever occurs last. Ongoing Ethics Committee oversight is required until the overall study closure process is complete. Refer to section 7.[ADDRESS_213637]. This is possible 
for the whole study or a single site.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 61 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  [IP_ADDRESS].  Study -wide Termination or Suspension  
Possible reasons for considering study suspension or termination of the study include but are not limited 
to: 
• Adverse events associated with the system or product under investigation which might 
endanger the safety or welfare of the subject  
• Observed/suspected performance different from the product’s design intent  
• Decision by [CONTACT_54467] (where the study is operating under regul atory body 
authority)  
• Technical issues during the manufacturing process  
[IP_ADDRESS].  Investigator/ Site Termination or Suspension  
Possible reasons for clinical investigator or site termination or suspension include but are not limited to:  
• Failure to obtain initial Ethi cs Committee approval or annual renewal of the study  
• Persistent non-compliance to the clinical investigation (e.g. failure to adhere to 
inclusion/exclusion criteria, failure to follow subjects per scheduled follow -ups)  
• Lack of enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial Agreement (e.g. failure to 
submit data in a timely manner, failure to follow -up on data queries and monitoring findings in a 
timely manner, etc.)  
• Ethics Committee suspension of the site  
• Fraud or fraudulent misconduct is discovered (as defined by [CONTACT_54468])  
• Investigator request (e.g. no longer able to support the study)  
14.9.3.  Procedures for Termination or Suspension  
[IP_ADDRESS].  Medtronic -Initiated and Regulatory Authority-I nitiated 
• Medtronic will promptly inform the clinical investigators of the termination or suspension and the reasons and inform the regulatory authority(ies) where required  
• In the case of study termination or suspension for reasons other than a temporary MEC/IRB/Head of Medical In stitution approval lapse, the investigator will promptly inform the 
MEC/IRB/Head of Medical Institution  
• In the case of study termination, the investigator must inform the subjects and may inform the personal physician of the subjects to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subject enrollment must stop until the suspension is lifted by 
[CONTACT_13735]  
• In the case of a study suspension, enrolled subjects should continue to be followed out of 
consideration of their sa fety, rights and welfare  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 62 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  [IP_ADDRESS].  Investigator-I nitiated 
• The investigator will inform Medtronic and provide a detailed written explanation of the 
termination or suspension  
• The investigator will promptly inform the institution (where required per regulatory requirem ents)  
• The investigator will promptly inform the MEC/IRB/Head of Medical Institution  
• The investigator will promptly inform the subjects and/or the personal physician of the subjects to ensure appropriate care and follow -up is provided 
• In the case of a study suspension, subjects enrolled should continue to be followed out of consideration of their safety, rights and welfare  
[IP_ADDRESS].  Ethics Committee-I nitiated 
• The investigator will inform Medtronic and provide a detailed written explanation of the termination or suspension within 5 business days  
• Subject enrollment must stop until the suspension is lifted  
• Subjects already enrolled should continue to be followed in accordance with MEC/IRB/Head of Medical Institution policy or its determination that an overriding safety concern or ethical issue is involved 
• The investigator will inform his/her institution (where required per local requirements)  
• The investigator will promptly inform the subjects, or legally -authorized designees or guardians 
and/or the personal physician of the subjects, with the rationale for the study termination or 
suspension  
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 63 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  15. References  
Alejandro A. Rabinstein, M. J. (2013). Paroxysmal Atrial Fibrillation in Cryptogenic Stroke:A Case –Control 
Study. Journal of Stroke and Cerbrovascular Disease , 1-7.  
Dariush Mozaffarian, E. J. -P. (2015). Heart Disease and Stroke Statistics —2015 Update: A Report From 
the American Heart Associatio n . Circulation, 29-322.  
L. M. Christensen, D. W. (2014). Paroxysmal atrial fibrillation occurs often in cryptogenic. European 
Journal of Neurology, 884- 889.  
Luciano A. Sposato, M. M. (2012). Newly Diagnosed Atrial Fibrillation after Acute Ischemic Stroke and 
Transient Ischemic Attack: Importance of Immediate and Prolonged Continuous Cardiac 
Monitoring. Journal of Stroke and Cerebrovascular Diseases , 210-216.  
Owen, A. (2009). Antithrombotic treatment for the primary prevention of stroke in patients with non  
valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis. International Journal of Cardiology, 1-6.  
Paul D. Ziegler, M., Taya V. Glotzer, M., Emile G. Daoud, M., D. George Wyse, M. P., Daniel E. Singer, M., 
Michael D. Ezekowit z, M. P., et al. (2010). Incidence of Newly Detected Atrial Arrhythmias via 
Implantable Devices in Patients With a History of Thromboembolic Events. Stroke, Journal of the American Heart Association, 256-260. 
Paul D. Ziegler, T. V. (2009). Incidence of New ly Detected Atrial Arrhythmias via Implantable Devices in 
Patients With a History of Thromboembolic Events. Stroke: Journal of the American Heart Association , 256-260. 
Ralph L. Sacco, M. M., Robert Adams, M. F., Greg Albers, M., Mark J. Alberts, M. F., Oscar Benavente, M., 
Karen Furie, M. M., et al. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke , 577-617.  
S. Adam Strickberger, M. J. (2005). Relationship between atrial tachyarrhythmias and sy mptoms. Heart 
Rhythm Society , 125-131. 
Tommaso Sanna, M. H.-C. (2014). Cryptogenic Stroke and Underlying Atrial Fibrillation. The new england 
journal of medicine , 2478-2486. 
William C. Choe, M. R. -C. (2015). A Comparison of Atrial Fibrillation Monitoring S trategies after 
Cryptogenic Stroke. The American Journal of Cardiology. 
 
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 64 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
   
  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 65 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  16. Version History  
Version  Summary of Changes  Author(s)/Title  
1.0 • Not Applicable, New Document’  Jennifer Heim, 
Principal Clinical 
Research Specialist  
2.0 • Table 1. Taryn Randall now monitoring contact [CONTACT_181033]. 
Rationale: Accuracy  Jennifer Heim, 
Principal Clinical 
Research Specialist  • Table 2. Clarified that there will be a CRO to manage blood 
samples. Rationale: Updated study design includes long term 
blood sample storage which will need to be managed by a CRO 
which is TBD.  
• Section 1 (Synopsis). Updated to reflect changes in study 
design which include: randomization (SoC vs LINQ), blood draw, additional study sites (was 30 now 40) and larger sample size (was 250, now 496). Study patients to be followed for [ADDRESS_213638]. Rationale: Medtronic business decision to make the 
study more robust.  
• Section 2 (Introduction). Study purpose and description 
updated to include randomized design, larger sample size(sites and patients) and longer study duration. Rationale: Medtronic 
business decision to make the study more robust.  
• Section 6 (Methodology). Study objectives updated based on 
changes in study design (randomization). Rationale: Medtronic 
business decision to make the study more robust.  
• Section 7 (Study Procedures). A dded randomization, blood 
draw, and cross over to study procedure table and updated visit descriptions as applicable. Added clarity around data collection only applicable to one study arm. Randomization section (7.8) added. Rationale: Medtronic business decision to 
make the study more robust.  
• Section 9 (Study Deviations). Added crossover as an example 
of a study deviation. Rationale: Clarity.  
• Section 13 (Statistical Methods and Data Analysis). Section 
updated to reflect revised study design and objectives. 
Rationale: Changes to study design.  
• Appendix I. Clarified that the CEC could serve as the EAC if 
desired. Rationale: To allow flexibility in study management.  
3.0 • Glossary added, and document format updated. Rationale: 
Align with current document template.  Christine Greening, 
Senior Principal 
Clinical Research Specialist  • Removed contact [CONTACT_3031]. Rationale: Contact [CONTACT_181034].  
• Study Description and Statistical Methods and Data Analysis: 
Removed stoppi[INVESTIGATOR_180993]. Rationale: Robust study with adequate data for analysis 
of all objectives.  
Stroke AF Clinical Investigation Plan  
  
18 December 2018  Version  4.0  Page 66 of 66 
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • Duration: Enrollment u pdated from 20 to 42 months  and study 
from 4.5 to 6.5 years . Rationale: Estimat e updated per 
observed enrollment rate.  
• Informed Consent: Updated best practice documentation to 
should document the informed consent process in the source 
documentation. Rationale: Clarity.  
• Study Procedures related to blood draw: Added “or if the 
patient declines”. Rationale: Clarity.  
• Study Procedures related to Reveal LINQ ICM removed 
requirements for continuous monitoring arm only. Rationale: 
Allow for consistency in data collection for subjects with an 
ICM. 
• Follow -up Visit Procedure: Removed “in -clinic”. Data may be 
collected remotely for subjects unable to return to the clinic for the follow up visit. Rationale: Reduce patient burden of 
attending in -clinic as all data may be captured remotely.  
• System Modification Procedu re: Removed “continuous 
monitoring arm only”. Rationale: Device modification should be 
reported for any subject with an ICM.  
• Data Review Committee: Steering Committee referenced in 
committee section. Removed contact [CONTACT_8972]. Rationale: Clarity as contac t details for all committees noted to be maintained 
separately.  
• Data Review Committee: Clinic Clinical Events Committee (CEC) 
review. “All” removed regarding reported arrhythmias. 
Rationale: Consistency with adjudication of time to first event.  
• Statistical Methods and Data Analysis. Add endpoint AF related 
hospi[INVESTIGATOR_059]. Rationale: Business decision for additional 
analysis.  
• Statistical Methods and Data Analysis. CareLink transmission 
may be used for censoring. Rationale: Clarity.  
• Confidentia lity: Added statement that a ll records and other 
information about subjects participating in this study will be treated as confidential. The identity of a subject will never be disclosed in the event that study data are published.  Rationale: 
Clarity.  
4.0 • Study Design: Updated the maximum of 200 subjects with 
lacunar stroke to a maximum of 50% (approximately 248) subjects. Rationale: Allow equal characterization of ischemic  
population.  
• Procedure table  and follow up :  Updated device data to include 
either interrogation or transmissions . Rationale: Include either 
mode of device data collection for patients completing visits in-
clinic or remotely, consistency with text as updated in CIP 
revision 3.[ADDRESS_213639]  
 